CA2159991A1 - Encapsulated sodium percarbonate particles, method of producing them, and washing-agent, cleaning-agent and bleaching-agent compositions containing them - Google Patents
Encapsulated sodium percarbonate particles, method of producing them, and washing-agent, cleaning-agent and bleaching-agent compositions containing themInfo
- Publication number
- CA2159991A1 CA2159991A1 CA002159991A CA2159991A CA2159991A1 CA 2159991 A1 CA2159991 A1 CA 2159991A1 CA 002159991 A CA002159991 A CA 002159991A CA 2159991 A CA2159991 A CA 2159991A CA 2159991 A1 CA2159991 A1 CA 2159991A1
- Authority
- CA
- Canada
- Prior art keywords
- sodium percarbonate
- weight
- coating
- particles
- peroxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B15/00—Peroxides; Peroxyhydrates; Peroxyacids or salts thereof; Superoxides; Ozonides
- C01B15/055—Peroxyhydrates; Peroxyacids or salts thereof
- C01B15/10—Peroxyhydrates; Peroxyacids or salts thereof containing carbon
- C01B15/106—Stabilisation of the solid compounds, subsequent to the preparation or to the crystallisation, by additives or by coating
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B15/00—Peroxides; Peroxyhydrates; Peroxyacids or salts thereof; Superoxides; Ozonides
- C01B15/055—Peroxyhydrates; Peroxyacids or salts thereof
- C01B15/10—Peroxyhydrates; Peroxyacids or salts thereof containing carbon
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D17/00—Detergent materials or soaps characterised by their shape or physical properties
- C11D17/0039—Coated compositions or coated components in the compositions, (micro)capsules
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/39—Organic or inorganic per-compounds
- C11D3/3942—Inorganic per-compounds
Abstract
Sodium percarbonate is often used, in the form of encapsulated particles, in washing and cleaning agents in order to increase their shelf life. Sodium percarbonate particles encapsulated as proposed by the invention have an envelope containing the products of the reaction between a di-alkali-metal tetraborate or alkali-metal pentaborate and aqueous hydrogen peroxide. Preferred envelope components are perborax compounds of the formula Na2B4O7.nH2O2 in which n is 1 or 4. The encapsulated sodium percarbonate particles are produced by coating the percarbonate particles using a solution containing the specified reaction products.
Washing, bleaching and cleaning agents containing sodium percarbonate particles encapsulated as proposed by the invention are characterized by their very long shelf life.
Washing, bleaching and cleaning agents containing sodium percarbonate particles encapsulated as proposed by the invention are characterized by their very long shelf life.
Description
Description - -This invention relates to coated sodium percarbonate particles, of which the coating contains a peroxygen-contAin;ng boron compound which imparts high storage stability to the sodium perc~rhon~te. The present invention also relates to a process for the production of the coated sodium percarbonate particles by application of one or more coating components, more particularly in the form of an aqueous solution con~ining them, to the sodium percarbonate to be coated and to detergent, cleaning and bleaching compositions contAin;ng coated sodium percarbonate particles according to the invention.
Sodium percarbonate (2 Na2CO3 3 H2O2) is used as an active oxygen component in detergents, bleaches and cleaning preparations. In view of the inadequate storage stability of sodium percarbonate in a humid environment and in the presence of various components of detergents and cleAn;ng preparations, sodium percarbonate has to be stabilized against the loss of active oxygen (O~). A key principle for stabilization is to ~LLound the sodium percarbonate particles with a coating of stabilizing components. Thus, it is known that sodium percarbonate can be coated with paraffin or polyethylene glycol.
Unfortunately, adequate long-term stability is not achieved in this way, in addition to which solubility in water is undesirably reduced. Even the application of a coating of alkali metal silicate to the sodium percar-bonate particles, as proposed in DE-OS 26 52 776, does not lead to adequate stabilization and, in addition, .
introduces an unwanted content of insoluble constituents.
In the processes known from DE-OS 24 17 572 and DE-OS 26 22 610, sodium sulfate and sodium carbonate or sodium sulfate, sodium carbonate and sodium silicate are used as coating components. In these processes, a solution of the coating components is sprayed onto sodium percar-bonate particles in a fluidized bed dryer. Adequate stabilization requires a large quantity of coating material which in turn leads to a correspon~ingly large reduction in the active oxygen content.
Although it is known from DE-PS 28 00 916 that a coating material cont~ining at least one boron compound from the group consisting of metaboric acid, orthoboric acid and tetraboric acid can be used for stabilizing sodium percarbonate, the stabilizing effect obtained in this way is described as inadequate in DE-OS 33 21 082, as demonstrated in the Comparison Examples. Instead, sodium percarbonate with a shell cont~ining sodium borate is described as advantageous. However, as the inventors of the present application discovered when copying the Examples of DE-OS 33 21 082, the borate and, optionally, other coating components - to achieve adequate stability - had to be present in the coating in such a quantity that the available active oxygen content of the sodium percarbonate thus stabilized was always below 14~ by weight. A further development of stabilization using borates is described in EP-A 0 487 256, although the coating process disclosed therein involves at least two stages and is therefore technically complicated.
Finally, DE-AS 24 58 326 describes a process for stabilizing sodium percarbonate, the storage stability of the pure product being increased, even in admixture with cleaning preparations. In this process, the sodium percarbonate is coated with a hydrophobic liquid organic compound to which sodium perborate powder is added. The - 21S999l disadvantage of this process lies in the need to use a hydrophobic liquid organic compound which has to be diluted with a lower alcohol in the interests of better handling. In addition, the quantities in which the coating chemicals are used, namely 5 to 20% by weight of sodium perborate and 5 to 10% by weight of hydrophobic organic com~o~.d, based on sodium percarbonate, are very high.
Coated sodium percarbonate particles consisting of a æodium percarbonate core and a coating of sodium perborate with the general formula NaB02 H202 n H20, where n is < 3, are known from DE-PS 26-51 442. Accord-ing to DE-PS 27 12 139, the coating may additionally contain sodium silicate and other water-binding substan-ces. To produce the coated sodium percarbonate particlesmentioned, sodium percarbonate is first wetted with water or an aqueous sodium silicate solution in such a small quantity that the sodium perborate is not converted into the tetrahydrate and is subsequently covered with an-hydrous sodium perborate. A further development of theprocess outlined above is described in DE-PS 28 iO 379 and comprises spraying sodium percarbonate with an aqueous solution of sodium perborate cont~;n;ng 50 to 500 g of sodium perborate tetrahydrate per liter of solution at 40 to 60C and with a sodium silicate solution and then completely or partly removing the water introduced.
As disclosed in hitherto unpublished German patent application P 43 06 399.3, the process described above can be considerably simplified by washing sodium percar-bonate produced by the wet method with a solution con-taining sodium perborate (NaB02 H202) in a solid/liquid separator after at least partial separation of the mother liquor. Despite the small quantity of coating required, high active oxygen stability is achieved in storage of the sodium percarbonate in admixture with a typical zeolite-containing detergent tower powder.
A coating containing perborate monohydrate or tetrahydrate has the advantage over a coating of sodium percarbonate with borates or boric acid that the active oxygen content of the sodium percarbonate particles is hardly affected.
The problem addressed by the present invention was further to improve the stabilization of sodium percar-bonate using new peroxygen-cont~;ning boron compounds and to provide new coated sodium percarbonate particles which, for the same boron content, would guarantee higher active oxygen stability in storage in admixture with detergent constituents than known sodium percarbonate particles having a perborate-cont~ining coating.
Accordingly, the present invention relates to coated sodium percarbonate particles consisting of a core of, essentially, sodium percarbonate and a coating containing at least one peroxygen-containing boron compound, charac-terized in that one or more reaction products from the reaction of a dialkali metal tetraborate or alkali metal pentaborate with aqueous hydrogen peroxide are present as the peroxygen-containing boron compound.
The core of the coated particles consists essential-ly of sodium percarbonate. By "essentially" is meant that the sodium percarbonate may contain secondary constituents from its production, such as for example soda and small quantities of sodium chloride and also crystallization retarders, for example a metaphosphate or a polycarboxylic acid and typical stabilizers, such as for example magnesium salts and sodium silicate. The term "essentially" also includes sodium percarbonate which already contains a coating of stabilizing compo-nents, for example selected from the group of phospho-nates, phosphates, soda, waterglass, magnesium salts, aminocarboxylates and aminophosphonates and also polymer-ic hydroxycarboxylates. In principle, any coatingcomponents already present may even be known boron compounds, although this does appear to be inappropriate where coated sodium percarbonate particles of low boron content are to be produced.
The sodium percarbonate to be used in the process according to the invention may-have been produced by a st~n~Ard process. St~n~rd production processes include in particular so-called wet processes in which soda and hydrogen peroxide are reacted in aqueous phase and sodium percarbonate is crystallized; and so-called spray proces-ses in which an aqueous solution containing soda and hydrogen peroxide is sprayed onto sodium percarbonate particles in a fluidized bed dryer; and so-called dry processes in which a concentrated hydrogen peroxide solution is reacted with anhydrous soda. If desired, a st~n~Ard production process may be followed by a standard coating process.
In their stabilizing shell, the coated sodium percarbonate particles according to the invention contain peroxygen-contA;ning reaction products which emanate from the reaction of a dialkali metal tetraborate or alkali metal pentaborate with aqueous hydrogen peroxide and which are completely or partly freed from water under st~n~rd drying conditions of correspondingly coated sodium percarbonate particles. The drying and water removal ph~ec may be accompanied by melting processes.
It is not yet known whether the resulting peroxygen-containing boron compounds are pure adducts of hydrogen peroxide with the tetraborate or pentaborate or compounds containing the structural element -B-0-0-H or -B-0-0-B-.
It may even be possible that the peroxygen-containing tetra- and pentaborate(s) undergo partial disproportiona-tion during the production-related drying process, so that a boric acid and a perborate containing the struc-tural element:
~~ ~~n~~{
~o~`o of `o~
known from so-called sodium perborate monohydrate may be present alongside one another in the coating.
According to Ullmann's Encyclopedia of Industrial Chemistry, 5th Edition (1985), Vol. A4, 2;70, the tetra-borates and pentaborates used for the formation of the peroxygen-contA;n;ng boron compounds mentioned above have the following anion structure:
_ HO--B O B--OH
o l~l ~B--O O--EI~
OH
The tetraborate and pentaborate contain lithium, sodium or potassium as cation, sodium being preferred.
Preferred coated sodium percarbonate particles contain a so-called perborax correspon~in~ to the general formula Na2B407 n Hz02 m H20, where n is an integer of 1 to 4 and m is an integer of 0 to 9, as the peroxygen-contA;n;ng boron compound in the coating. 2 To 4 mols of ~ydLoyen peroxide and 0 to 2 mols of water are preferably bound per mol of tetraborate. In a particularly prefer-red embodiment, the coating essentially contains Na2B~07 4 H20z.
In addition to the peroxygen-cont~; n ing perboron compounds according to the invention, such as in par-ticular perborax corresponding to the general formula NazB~O7 4 H2O2, the coating may additionally contain other known stabilizing coating components in uniform distribution, for example those already mentioned in the preamble. If desired, the coating according to the - 21S999l invention may be surrounded by other layers containing other stabilizers than the peroxygen-containing perboron compounds used in accordance with the invention and optionally by other layers containing individual consti-tuents of typical detergent and cleaning compositions,for example zeolites. These additional layers may have been applied to the sodium percarbonate particles coated in accordance with the invention by standard methods, i.e. in particular by spray, mixing and granulation processes.
The sodium percarbonate particles coated in accord-ance with the invention may contain widely varying quantities of coating material. Although quantities of 1 to more than 30% by weight, based on sodium percar-bonate, are possible, quantities of 1 to 10~ by weightand preferably 2 to 6~ by weight of coating material have proved to be advantageous in practice. On the one hand, these limited quantities provide for adequate stabiliza-tion of the sodium percarbonate against losses of active oxygen during storage in humid conditions in the presence of typical detergent, cleaning and bleaching composi-tions; on the other hand, the boron content of the coated sodium percarbonate remains at a low level.
As already mentioned, the single-layer or multiple layer coating of the sodium percarbonate particles according to the invention may contain other coating components in addition to the reaction products of hydrogen peroxide with a tetraborate or pentaborate.
Advantageously, the coating as a whole contains more than 50% by weight and, in particular, more than 70% by weight of the above-mentioned reaction products of hydrogen peroxide with a tetraborate or pentaborate and less than 50% by weight and in particular less than 30% by weight of other stabilizing compounds. Sodium percarbonate particles coated in accordance with the invention with a single coating layer essentially containing only the peroxygen-containing boron compounds to be used in accordance with the invention show an extremely high level of stability in storage in the presence of deter-gent tower powders which is not achieved where st~n~rdperborate is used on its own, despite the same boron content. This is extremely surprising because perborax with the formula Na2B407 4 H202 is ~ess stable as such than sodium perborate monohydrate for example.
The sodium percarbonate particles coated in accord-ance with the invention may be obtained by application of at least one peroxygen-contA;ning boron compound and, if desired, other coating components, preferably using an aqueous solution cont~; n i~g the coating components, to particles consisting essentially of sodium percarbonate and, if nec~ccAry~ drying the resulting moist particles.
The process is characterized in that one or more reaction products from the reaction of a dialkali metal tetra-borate or alkali metal pentaborate with aqueous hydrogen peroxide is used as the peroxygen-containing boron compound.
The coating components are preferably applied to the sodium percarbonate particles in the form of one or more aqueous solutions. The reaction mixture from the reac-tion of a tetraborate or pentaborate with hydrogenperoxide is best directly used.
If desired, the boron compounds cont~in;ng active oxygen may be recovered from the reaction mixture in the form of a further concentrated solution or even as a solid by partial or complete evaporation of the water present and may be used as such for the process according to the invention. The reaction mixture is best directly prepared in such a way that the desired concentration of peroxygen-containing boron compounds is maintained. By virtue of the high solubility of the reaction products of tetraborates and pentaborates with hydrogen peroxide, highly concentrated solutions of the peroxygen-containing boron compounds are obtained. Solutions such as these have the advantage that, when they are applied to sodium percarbonate particles by a spray nozzle, no blockages of the spray nozzle and hence no malfunctions occur. At the same time, only a small quantity of water has to be removed in the drying process. In the preparation of the reaction mixture, the reactants are used in such a guan-tity that an atomic ratio of boron to active oxygen of1:0.2 to 1:1.5 is obtained. However, an atomic ratio of boron to active oxygen of 1:0.5 to 1:1.25 is preferred, an atomic ratio of 1 to substantially 1 being particular-ly preferred. In a particularly preferred embodiment, the solution to be applied to the sodium percarbonate particles contains a perborax with the general formula Na2B407 n H202, where n is an integer of 1 to 4, prefer-ably 2 to 4 and, more preferably, approximately 4. Where a solution cont~;n;~g Na2B407 4 H202 is used, it is of advantage if the solution additionally contains a small excess of hydrogen peroxide corresponding to an atomic ratio of boron to active oxygen of approximately 1:1.05 to 1.15. Solutions such as these may readily be obtained by introducing borax with stirring into an aqueous hydro-gen peroxide solution. Solutions cont~;n;ng, for exam-ple, 20 to 50% by weight and, more particularly, 25 to 40% by weight of perborax with the formula Na2B407 n H202, where n is an integer of 2 to 4, can be prepared in this way for the process according to the invention.
The peroxygen-containing boron compound to be used in accordance with the invention may be continuously or discontinuously applied to particles consisting essen-tially of sodium percarbonate in one or more stages by standard methods. The particles to be coated may either be dry or may contain residual moisture from their -production process. Accordingly, it is even possible to use, for example, centrifuge-moist or partly dried sodium percarbonate. Coated sodium percarbonate particles according to the invention may be obtained by mixing surface-moist sodium percarbonate with powder-form perborax and, if nec~sCAry~ subsequent drying. However, it is of greater advantage to-apply a solution of the coating components to sodium percarbonate particles.
Suitable proc~Ccec are, for example: spraying a solution onto the particles with simultaneous mixing; suitable mixers are, for example, spray mixers, such as rotating tubes, tumble mixers, pan granulators. In an alternative to the embodiment mentioned above, sodium percarbonate produced in a wet process is treated with an aqueous solution containing a peroxygen-cont~ining boron compound according to the invention in a washing installation, for example a solid/liquid separator, and the product thus treated is dried after the removal of excess solution.
This embodiment corresponds to the embodiment according to hitherto unpublished German patent application P 43 06 399.3 except that a solution contA;n;ng sodium perborate (NaB02 H202) is used in the process according to the earlier application. In one particularly advantageous embodiment of the process according to the invention, the aqueous solution is sprayed onto the particles to be coated in a fluidized bed in which the particles are kept in a fluidized state. The particles moistened with the solution sprayed on are simultaneously or subsequently dried. Where a fluidized bed arrangement is used, spraying and drying may be carried out at the same time by using air heated to the drying temperature for fluid-ization .
The solution cont~;n;ng the peroxygen-containing boron compounds to be used in accordance with the inven-tion and optionally other coating components may be at room temperature or at a temperature of up to about 60Cduring the spraying process. Where particularly highly concentrated solutions are used, it is best to heat them, preferably to a temperature of 30 to 50C. Where the solution to be used is prepared from a tetraborate or pentaborate and hydrogen peroxide, the temperature of the solution immediately before it is used will be approxi-mately in the range mentioned under the effect of the heat of solution and the heat of reaction. Instead of preparing the solution from the reactants, it may also be produced by dissolving perborax with the empirical formula Na2B407 4 H202, as described for example in DE-PS 548 432, in water; up to l kg perborax can be dis-solved in 1 liter of water at room temperature.
The moist coated sodium percarbonate obtained by spraying is dried under conditions typically applied in the drying of sodium percarbonate. Accordingly, the drying temperature is in the range from 30 to 90C, preferably in the range from 50 to 80C and more prefer-ably in the range from 50 to 70C. The drying tempera-ture is understood to be the temperature of the particles to be dried. Accordingly, in the particularly preferred embodiment where the process is carried out in a fluid-ized dryer, the fluidized bed temperature is in the above-mentioned temperature range. The temperature at which the drying gas enters the fluidized dryer will therefore be above the fluidized bed temperature.
The sodium percarbonate particles coated in accord-ance with the invention may be used as bleaching com-ponent in detergents, cleaning and bleaching composi-tions. Detergent, cleaning and bleaching compositions containing sodium percarbonate particles coated in accordance with the invention are distinguished by the fact that the sodium percarbonate present therein has an unexpectedly high storage stability, so that there is only a very gradual loss of active oxygen during the storage of such compositions under typical conditions.
The storage stability of sodium percarbonate coated in accordance with the invention in the compositions men-tioned exceeds the level obtained with known coatedsodium percarbonate particles for comparable quantities of coating material and a high starting 0, content.
The detergent, cle~ning and bleaching compositions cont~in;ng sodium percarbonate coated in accor~nce with the invention consist of 1 to 99% by weight of the coated sodium percarbonate and, for the rest (h~l~nce to 100% by weight), of other typical components of such composi-tions. Whereas the content of sodium percarbonate in detergents generally does not exceed 20% by weight, it lS may be distinctly higher in bleaching and cleaning compositions.
The detergent, cleaning and bleaching compositions cont~in;ng sodium percarbonate coated in accordance with the invention contain other components typical of such compositions in the usual concentrations in addition to the active oxygen compound mentioned above. The other components in question include in particular 1. surfactants from the group of cationic, anionic, nonionic, amphoteric or ampholytic surfactants;
Sodium percarbonate (2 Na2CO3 3 H2O2) is used as an active oxygen component in detergents, bleaches and cleaning preparations. In view of the inadequate storage stability of sodium percarbonate in a humid environment and in the presence of various components of detergents and cleAn;ng preparations, sodium percarbonate has to be stabilized against the loss of active oxygen (O~). A key principle for stabilization is to ~LLound the sodium percarbonate particles with a coating of stabilizing components. Thus, it is known that sodium percarbonate can be coated with paraffin or polyethylene glycol.
Unfortunately, adequate long-term stability is not achieved in this way, in addition to which solubility in water is undesirably reduced. Even the application of a coating of alkali metal silicate to the sodium percar-bonate particles, as proposed in DE-OS 26 52 776, does not lead to adequate stabilization and, in addition, .
introduces an unwanted content of insoluble constituents.
In the processes known from DE-OS 24 17 572 and DE-OS 26 22 610, sodium sulfate and sodium carbonate or sodium sulfate, sodium carbonate and sodium silicate are used as coating components. In these processes, a solution of the coating components is sprayed onto sodium percar-bonate particles in a fluidized bed dryer. Adequate stabilization requires a large quantity of coating material which in turn leads to a correspon~ingly large reduction in the active oxygen content.
Although it is known from DE-PS 28 00 916 that a coating material cont~ining at least one boron compound from the group consisting of metaboric acid, orthoboric acid and tetraboric acid can be used for stabilizing sodium percarbonate, the stabilizing effect obtained in this way is described as inadequate in DE-OS 33 21 082, as demonstrated in the Comparison Examples. Instead, sodium percarbonate with a shell cont~ining sodium borate is described as advantageous. However, as the inventors of the present application discovered when copying the Examples of DE-OS 33 21 082, the borate and, optionally, other coating components - to achieve adequate stability - had to be present in the coating in such a quantity that the available active oxygen content of the sodium percarbonate thus stabilized was always below 14~ by weight. A further development of stabilization using borates is described in EP-A 0 487 256, although the coating process disclosed therein involves at least two stages and is therefore technically complicated.
Finally, DE-AS 24 58 326 describes a process for stabilizing sodium percarbonate, the storage stability of the pure product being increased, even in admixture with cleaning preparations. In this process, the sodium percarbonate is coated with a hydrophobic liquid organic compound to which sodium perborate powder is added. The - 21S999l disadvantage of this process lies in the need to use a hydrophobic liquid organic compound which has to be diluted with a lower alcohol in the interests of better handling. In addition, the quantities in which the coating chemicals are used, namely 5 to 20% by weight of sodium perborate and 5 to 10% by weight of hydrophobic organic com~o~.d, based on sodium percarbonate, are very high.
Coated sodium percarbonate particles consisting of a æodium percarbonate core and a coating of sodium perborate with the general formula NaB02 H202 n H20, where n is < 3, are known from DE-PS 26-51 442. Accord-ing to DE-PS 27 12 139, the coating may additionally contain sodium silicate and other water-binding substan-ces. To produce the coated sodium percarbonate particlesmentioned, sodium percarbonate is first wetted with water or an aqueous sodium silicate solution in such a small quantity that the sodium perborate is not converted into the tetrahydrate and is subsequently covered with an-hydrous sodium perborate. A further development of theprocess outlined above is described in DE-PS 28 iO 379 and comprises spraying sodium percarbonate with an aqueous solution of sodium perborate cont~;n;ng 50 to 500 g of sodium perborate tetrahydrate per liter of solution at 40 to 60C and with a sodium silicate solution and then completely or partly removing the water introduced.
As disclosed in hitherto unpublished German patent application P 43 06 399.3, the process described above can be considerably simplified by washing sodium percar-bonate produced by the wet method with a solution con-taining sodium perborate (NaB02 H202) in a solid/liquid separator after at least partial separation of the mother liquor. Despite the small quantity of coating required, high active oxygen stability is achieved in storage of the sodium percarbonate in admixture with a typical zeolite-containing detergent tower powder.
A coating containing perborate monohydrate or tetrahydrate has the advantage over a coating of sodium percarbonate with borates or boric acid that the active oxygen content of the sodium percarbonate particles is hardly affected.
The problem addressed by the present invention was further to improve the stabilization of sodium percar-bonate using new peroxygen-cont~;ning boron compounds and to provide new coated sodium percarbonate particles which, for the same boron content, would guarantee higher active oxygen stability in storage in admixture with detergent constituents than known sodium percarbonate particles having a perborate-cont~ining coating.
Accordingly, the present invention relates to coated sodium percarbonate particles consisting of a core of, essentially, sodium percarbonate and a coating containing at least one peroxygen-containing boron compound, charac-terized in that one or more reaction products from the reaction of a dialkali metal tetraborate or alkali metal pentaborate with aqueous hydrogen peroxide are present as the peroxygen-containing boron compound.
The core of the coated particles consists essential-ly of sodium percarbonate. By "essentially" is meant that the sodium percarbonate may contain secondary constituents from its production, such as for example soda and small quantities of sodium chloride and also crystallization retarders, for example a metaphosphate or a polycarboxylic acid and typical stabilizers, such as for example magnesium salts and sodium silicate. The term "essentially" also includes sodium percarbonate which already contains a coating of stabilizing compo-nents, for example selected from the group of phospho-nates, phosphates, soda, waterglass, magnesium salts, aminocarboxylates and aminophosphonates and also polymer-ic hydroxycarboxylates. In principle, any coatingcomponents already present may even be known boron compounds, although this does appear to be inappropriate where coated sodium percarbonate particles of low boron content are to be produced.
The sodium percarbonate to be used in the process according to the invention may-have been produced by a st~n~Ard process. St~n~rd production processes include in particular so-called wet processes in which soda and hydrogen peroxide are reacted in aqueous phase and sodium percarbonate is crystallized; and so-called spray proces-ses in which an aqueous solution containing soda and hydrogen peroxide is sprayed onto sodium percarbonate particles in a fluidized bed dryer; and so-called dry processes in which a concentrated hydrogen peroxide solution is reacted with anhydrous soda. If desired, a st~n~Ard production process may be followed by a standard coating process.
In their stabilizing shell, the coated sodium percarbonate particles according to the invention contain peroxygen-contA;ning reaction products which emanate from the reaction of a dialkali metal tetraborate or alkali metal pentaborate with aqueous hydrogen peroxide and which are completely or partly freed from water under st~n~rd drying conditions of correspondingly coated sodium percarbonate particles. The drying and water removal ph~ec may be accompanied by melting processes.
It is not yet known whether the resulting peroxygen-containing boron compounds are pure adducts of hydrogen peroxide with the tetraborate or pentaborate or compounds containing the structural element -B-0-0-H or -B-0-0-B-.
It may even be possible that the peroxygen-containing tetra- and pentaborate(s) undergo partial disproportiona-tion during the production-related drying process, so that a boric acid and a perborate containing the struc-tural element:
~~ ~~n~~{
~o~`o of `o~
known from so-called sodium perborate monohydrate may be present alongside one another in the coating.
According to Ullmann's Encyclopedia of Industrial Chemistry, 5th Edition (1985), Vol. A4, 2;70, the tetra-borates and pentaborates used for the formation of the peroxygen-contA;n;ng boron compounds mentioned above have the following anion structure:
_ HO--B O B--OH
o l~l ~B--O O--EI~
OH
The tetraborate and pentaborate contain lithium, sodium or potassium as cation, sodium being preferred.
Preferred coated sodium percarbonate particles contain a so-called perborax correspon~in~ to the general formula Na2B407 n Hz02 m H20, where n is an integer of 1 to 4 and m is an integer of 0 to 9, as the peroxygen-contA;n;ng boron compound in the coating. 2 To 4 mols of ~ydLoyen peroxide and 0 to 2 mols of water are preferably bound per mol of tetraborate. In a particularly prefer-red embodiment, the coating essentially contains Na2B~07 4 H20z.
In addition to the peroxygen-cont~; n ing perboron compounds according to the invention, such as in par-ticular perborax corresponding to the general formula NazB~O7 4 H2O2, the coating may additionally contain other known stabilizing coating components in uniform distribution, for example those already mentioned in the preamble. If desired, the coating according to the - 21S999l invention may be surrounded by other layers containing other stabilizers than the peroxygen-containing perboron compounds used in accordance with the invention and optionally by other layers containing individual consti-tuents of typical detergent and cleaning compositions,for example zeolites. These additional layers may have been applied to the sodium percarbonate particles coated in accordance with the invention by standard methods, i.e. in particular by spray, mixing and granulation processes.
The sodium percarbonate particles coated in accord-ance with the invention may contain widely varying quantities of coating material. Although quantities of 1 to more than 30% by weight, based on sodium percar-bonate, are possible, quantities of 1 to 10~ by weightand preferably 2 to 6~ by weight of coating material have proved to be advantageous in practice. On the one hand, these limited quantities provide for adequate stabiliza-tion of the sodium percarbonate against losses of active oxygen during storage in humid conditions in the presence of typical detergent, cleaning and bleaching composi-tions; on the other hand, the boron content of the coated sodium percarbonate remains at a low level.
As already mentioned, the single-layer or multiple layer coating of the sodium percarbonate particles according to the invention may contain other coating components in addition to the reaction products of hydrogen peroxide with a tetraborate or pentaborate.
Advantageously, the coating as a whole contains more than 50% by weight and, in particular, more than 70% by weight of the above-mentioned reaction products of hydrogen peroxide with a tetraborate or pentaborate and less than 50% by weight and in particular less than 30% by weight of other stabilizing compounds. Sodium percarbonate particles coated in accordance with the invention with a single coating layer essentially containing only the peroxygen-containing boron compounds to be used in accordance with the invention show an extremely high level of stability in storage in the presence of deter-gent tower powders which is not achieved where st~n~rdperborate is used on its own, despite the same boron content. This is extremely surprising because perborax with the formula Na2B407 4 H202 is ~ess stable as such than sodium perborate monohydrate for example.
The sodium percarbonate particles coated in accord-ance with the invention may be obtained by application of at least one peroxygen-contA;ning boron compound and, if desired, other coating components, preferably using an aqueous solution cont~; n i~g the coating components, to particles consisting essentially of sodium percarbonate and, if nec~ccAry~ drying the resulting moist particles.
The process is characterized in that one or more reaction products from the reaction of a dialkali metal tetra-borate or alkali metal pentaborate with aqueous hydrogen peroxide is used as the peroxygen-containing boron compound.
The coating components are preferably applied to the sodium percarbonate particles in the form of one or more aqueous solutions. The reaction mixture from the reac-tion of a tetraborate or pentaborate with hydrogenperoxide is best directly used.
If desired, the boron compounds cont~in;ng active oxygen may be recovered from the reaction mixture in the form of a further concentrated solution or even as a solid by partial or complete evaporation of the water present and may be used as such for the process according to the invention. The reaction mixture is best directly prepared in such a way that the desired concentration of peroxygen-containing boron compounds is maintained. By virtue of the high solubility of the reaction products of tetraborates and pentaborates with hydrogen peroxide, highly concentrated solutions of the peroxygen-containing boron compounds are obtained. Solutions such as these have the advantage that, when they are applied to sodium percarbonate particles by a spray nozzle, no blockages of the spray nozzle and hence no malfunctions occur. At the same time, only a small quantity of water has to be removed in the drying process. In the preparation of the reaction mixture, the reactants are used in such a guan-tity that an atomic ratio of boron to active oxygen of1:0.2 to 1:1.5 is obtained. However, an atomic ratio of boron to active oxygen of 1:0.5 to 1:1.25 is preferred, an atomic ratio of 1 to substantially 1 being particular-ly preferred. In a particularly preferred embodiment, the solution to be applied to the sodium percarbonate particles contains a perborax with the general formula Na2B407 n H202, where n is an integer of 1 to 4, prefer-ably 2 to 4 and, more preferably, approximately 4. Where a solution cont~;n;~g Na2B407 4 H202 is used, it is of advantage if the solution additionally contains a small excess of hydrogen peroxide corresponding to an atomic ratio of boron to active oxygen of approximately 1:1.05 to 1.15. Solutions such as these may readily be obtained by introducing borax with stirring into an aqueous hydro-gen peroxide solution. Solutions cont~;n;ng, for exam-ple, 20 to 50% by weight and, more particularly, 25 to 40% by weight of perborax with the formula Na2B407 n H202, where n is an integer of 2 to 4, can be prepared in this way for the process according to the invention.
The peroxygen-containing boron compound to be used in accordance with the invention may be continuously or discontinuously applied to particles consisting essen-tially of sodium percarbonate in one or more stages by standard methods. The particles to be coated may either be dry or may contain residual moisture from their -production process. Accordingly, it is even possible to use, for example, centrifuge-moist or partly dried sodium percarbonate. Coated sodium percarbonate particles according to the invention may be obtained by mixing surface-moist sodium percarbonate with powder-form perborax and, if nec~sCAry~ subsequent drying. However, it is of greater advantage to-apply a solution of the coating components to sodium percarbonate particles.
Suitable proc~Ccec are, for example: spraying a solution onto the particles with simultaneous mixing; suitable mixers are, for example, spray mixers, such as rotating tubes, tumble mixers, pan granulators. In an alternative to the embodiment mentioned above, sodium percarbonate produced in a wet process is treated with an aqueous solution containing a peroxygen-cont~ining boron compound according to the invention in a washing installation, for example a solid/liquid separator, and the product thus treated is dried after the removal of excess solution.
This embodiment corresponds to the embodiment according to hitherto unpublished German patent application P 43 06 399.3 except that a solution contA;n;ng sodium perborate (NaB02 H202) is used in the process according to the earlier application. In one particularly advantageous embodiment of the process according to the invention, the aqueous solution is sprayed onto the particles to be coated in a fluidized bed in which the particles are kept in a fluidized state. The particles moistened with the solution sprayed on are simultaneously or subsequently dried. Where a fluidized bed arrangement is used, spraying and drying may be carried out at the same time by using air heated to the drying temperature for fluid-ization .
The solution cont~;n;ng the peroxygen-containing boron compounds to be used in accordance with the inven-tion and optionally other coating components may be at room temperature or at a temperature of up to about 60Cduring the spraying process. Where particularly highly concentrated solutions are used, it is best to heat them, preferably to a temperature of 30 to 50C. Where the solution to be used is prepared from a tetraborate or pentaborate and hydrogen peroxide, the temperature of the solution immediately before it is used will be approxi-mately in the range mentioned under the effect of the heat of solution and the heat of reaction. Instead of preparing the solution from the reactants, it may also be produced by dissolving perborax with the empirical formula Na2B407 4 H202, as described for example in DE-PS 548 432, in water; up to l kg perborax can be dis-solved in 1 liter of water at room temperature.
The moist coated sodium percarbonate obtained by spraying is dried under conditions typically applied in the drying of sodium percarbonate. Accordingly, the drying temperature is in the range from 30 to 90C, preferably in the range from 50 to 80C and more prefer-ably in the range from 50 to 70C. The drying tempera-ture is understood to be the temperature of the particles to be dried. Accordingly, in the particularly preferred embodiment where the process is carried out in a fluid-ized dryer, the fluidized bed temperature is in the above-mentioned temperature range. The temperature at which the drying gas enters the fluidized dryer will therefore be above the fluidized bed temperature.
The sodium percarbonate particles coated in accord-ance with the invention may be used as bleaching com-ponent in detergents, cleaning and bleaching composi-tions. Detergent, cleaning and bleaching compositions containing sodium percarbonate particles coated in accordance with the invention are distinguished by the fact that the sodium percarbonate present therein has an unexpectedly high storage stability, so that there is only a very gradual loss of active oxygen during the storage of such compositions under typical conditions.
The storage stability of sodium percarbonate coated in accordance with the invention in the compositions men-tioned exceeds the level obtained with known coatedsodium percarbonate particles for comparable quantities of coating material and a high starting 0, content.
The detergent, cle~ning and bleaching compositions cont~in;ng sodium percarbonate coated in accor~nce with the invention consist of 1 to 99% by weight of the coated sodium percarbonate and, for the rest (h~l~nce to 100% by weight), of other typical components of such composi-tions. Whereas the content of sodium percarbonate in detergents generally does not exceed 20% by weight, it lS may be distinctly higher in bleaching and cleaning compositions.
The detergent, cleaning and bleaching compositions cont~in;ng sodium percarbonate coated in accordance with the invention contain other components typical of such compositions in the usual concentrations in addition to the active oxygen compound mentioned above. The other components in question include in particular 1. surfactants from the group of cationic, anionic, nonionic, amphoteric or ampholytic surfactants;
2. inorganic and/or organic builders of which the main function is to sequester or complex the metal ions responsible for the hardness of water, for example zeolites, polyphosphates, aminopolyacetic acids and aminopolyphosphonic acids and also polyoxycarboxylic acids;
3. alkaline and inorganic electrolytes, such as for example alkanolamines and silicates, carbonates and sulfates;
4. bleach activators from the group of N-acyl compounds and O-acyl compounds, for example tetraacetyl ethylenediamine (TAED);
5. other constituents of the compositions may be stabilizers for peroxides, such as in particular magnesium salts, redeposition inhibitors, optical brighteners, foam inhibitors, enzymes, disinfec-tants, corrosion inhibitors, fragrances, dyes and pH
regulators. Particulars of individual compounds b~longing to classes 1 to 5 can be found, for example, in DE-OS 33 21 082, pages 14-30.
The sodium percarbonate particles coated in accord-ance with the invention show surprisingly high active oxygen stability both per se and in admixture with detergent, cleaning and bleaching compositions. This high degree of stability is surprisingly achieved with a quantity of coating material of a few percent, based on sodium percarbonate. Although it was known that boric acids, borates and sodium perborate were extremely effective as coating components, the effectiveness of the peroxygen-containing boron compounds preferably used in accordance with the invention eyce~c that of known boron compounds. The process according to the invention may be carried out very simply: by virtue of the very high solubility of perborax and other peroxygen-containing boron compounds to be used in accordance with the inven-tion, an effective coating layer can be obtained in a single process step. In addition, there are no malfunc-tions attributable to blockage of the nozzle. The consumption of energy for drying is also kept very low.
The invention is illustrated by the following Examples.
Example 1 Sodium percarbonate produced by reaction of soda with hydrogen peroxide in aqueous phase and having an active oxygen content (a) of 14.2% by weight was coated in a mixer with a solution cont~;n;ng perborax corre-spon~ing to the general formula Na2B407 4 H202:
The coating solution is prepared by dissolving 100.2 g of borax (Na2B407 lQ H20) in 115.4 g of a 35% by weight aqueous hydrogen peroxide-solution with stirring and moderate spontaneous heating. The solution contains 41%
by weight of Na2B407 4 H20 and 2.2% by weight of H202.
The atomic ratio of boron to active oxygen in the solution is 1:1.13.
1500 g of sodium percarbonate are sprayed with 183 g of the above-mentioned solution in a laboratory plough-share mixer and the moist product is dried at 60C in a fluidized bed dryer.
0~ content of the coated sodium percarbonate: 14.4%
by weight; boron content of the coated sodium percar-bonate: 0.61% by weight, calculated from the quantity of Na2B407 4 H202 applied and based on coated sodium percar-bonate. The a stability of the coated sodium percar-bonate added to a commercial zeolite-cont~;n;ng detergent tower powder (Persil Supra TP) - 15 parts by weight of coated sodium percarbonate and 85 parts by weight of tower powder - during storage of the mixture under humid conditions in detergent packs is shown in the Table.
Example 2 Sodium percarbonate (according to Example 1) was sprayed with a perborax (Na2B407 4 H202)-containing solution and simultaneously dried in a fluidized bed dryer.
The solution was prepared by dissolving borax in 19.5% by weight H202 solution. Content of Na2B407 4 H202 31.2~ by weight; atomic ratio of boron to active oxygen 1:1. The solution was sprayed onto the percarbonate through a two-component nozzle at a fluidized bed temper-ature of 50-C (entry temperature of the drying air llO-C). The quantity sprayed corresponded to 5 parts by weight of perborax per 100 parts by weight of sodium percarbonate; O.content of the coated sodium percarbonate 14.2% by weight. The a stability of the coated sodium percarbonate added to a detergent powder is shown in the Table (tower powder and mixing ratio as in Example 1).
Example 3 Example 2 was repeated with the difference that the spray solution contained perborax with the formula Na2B407 2 H202; content 28.7% by weight; atomic ratio of boron to active oxygen 1:1.
Quantity of coating 5% by weight, based on sodium percarbonate. a content of the coated sodium percar-bonate 14.0% by weight. The a stability in a detergent tower powder is again shown in the Table (tower powder and mixing ratio as in Example 1).
Example 4 Centrifuge-moist sodium percarbonate - prepared by reaction of soda with hydrogen peroxide in aqueous phase in the presence of sodium chloride and sodium hexameta-phosphate and crystallization - was aftertreated in the centrifuge by washing with a perborax solution (33% by weight, based on Na2B407 4 H202) after removal of the mother liquor and subsequently dried in a fluidized bed dryer. The quantity of Na2B407 4 H202 applied corre-sponded to 2.5% by weight, based on sodium percarbonate.
The boron content was approximately 0.3~ by weight. The .
-a content of the coated percarbonate was 14.2% by weight.
The storage stability is shown in the Table.
Comparison Example ~
Sodium percarbonate was coated with 5% by weight of orthoboric acid, based on sodium percarbonate, by the process according to DE-PS 28 00 916 (see Example A6 of this document). a content of the coated sodium percar-bonate 13.4% by weight; boron content, based on coated sodium percarbonate, 0.83% by weight. The stability data during storage in the detergent mixture are shown in the Table.
Comparison Example 2 Sodium percarbonate was sprayed with an a~ueous borax solution (concentration 35% by weight) in a mixer (as in Example 1), the quantity of borax sprayed on amounting to 5 parts by weight per 100 parts by weight of sodium percarbonate. The material was then dried at 70C.
a content 13.5% by weight; boron content of the coated percarbonate 0.55% by weight, calculated from the borax applied on the assumption that borax was converted into Na2B407 5 H20 during drying.
Comparison Example 3 Sodium percarbonate was coated with sodium perborate and waterglass in accordance with DE-PS 28 10 379. The quantity of coating corresponded to 6% by weight of sodium perborate monohydrate and 1% by weight of water-glass. a content of the coated sodium percarbonate 14.3%
by weight;= boron content of the coated sodium percar-bonate (calculated from the quantity of NaB02 H202 applied) 0.62% by weight. The stability data in a detergent composition are shown in the Table.
To evaluate stability, coated sodium percarbonate of the Examples and Comparison Examples was stored in admixture with a commercial phosphate-free but zeolite-cont~;n;ng-detergent tower powder (Persil Supra TP) -mixing ratio 15:85 - in sealed detergent packs (0.4 1) ~ placed in a climatic chamber at a constant 30C/80%
relative humidity. The results of the active oxygen measurements of the mixtures carried out in the usual way at the beginn;ng and after storage for 2, 4 and 8 weeks are shown in the Table. For substantially the same boron content, sodium percarbonate particles coated in accord-ance with the invention show a higher stability in storage than the sodium percarbonate particles coated with boric acid, borax or perborate monohydrate.
~n x U --~ .. . .
~ ~o o ~ ~1 ~1 o -.C .
~ In ~ ~- ~ ~o o o ~
o oo a~ o _ _ C ~ ~
~Q i o I`
R
t, ~
R ~
~ J
--~ ~ er ~ o ~ ~ U~ ~
R ~1 ~q ~ 0 0 0 J ~
~ O ~ o o o o o o o wX V ~ r o~
R ~ o d~ ~ ~
E~m o ~n v ~J N ~1 N O
~ O
'_ ~ ~ ~ ~ ~ 0 ~1 ~ ~
R a:~ ~ m~
u,~-- zu~ z~ Zu. z~ m~ z~ z~O
~ o ,1 ,I h ~1 ~7 X O O X
regulators. Particulars of individual compounds b~longing to classes 1 to 5 can be found, for example, in DE-OS 33 21 082, pages 14-30.
The sodium percarbonate particles coated in accord-ance with the invention show surprisingly high active oxygen stability both per se and in admixture with detergent, cleaning and bleaching compositions. This high degree of stability is surprisingly achieved with a quantity of coating material of a few percent, based on sodium percarbonate. Although it was known that boric acids, borates and sodium perborate were extremely effective as coating components, the effectiveness of the peroxygen-containing boron compounds preferably used in accordance with the invention eyce~c that of known boron compounds. The process according to the invention may be carried out very simply: by virtue of the very high solubility of perborax and other peroxygen-containing boron compounds to be used in accordance with the inven-tion, an effective coating layer can be obtained in a single process step. In addition, there are no malfunc-tions attributable to blockage of the nozzle. The consumption of energy for drying is also kept very low.
The invention is illustrated by the following Examples.
Example 1 Sodium percarbonate produced by reaction of soda with hydrogen peroxide in aqueous phase and having an active oxygen content (a) of 14.2% by weight was coated in a mixer with a solution cont~;n;ng perborax corre-spon~ing to the general formula Na2B407 4 H202:
The coating solution is prepared by dissolving 100.2 g of borax (Na2B407 lQ H20) in 115.4 g of a 35% by weight aqueous hydrogen peroxide-solution with stirring and moderate spontaneous heating. The solution contains 41%
by weight of Na2B407 4 H20 and 2.2% by weight of H202.
The atomic ratio of boron to active oxygen in the solution is 1:1.13.
1500 g of sodium percarbonate are sprayed with 183 g of the above-mentioned solution in a laboratory plough-share mixer and the moist product is dried at 60C in a fluidized bed dryer.
0~ content of the coated sodium percarbonate: 14.4%
by weight; boron content of the coated sodium percar-bonate: 0.61% by weight, calculated from the quantity of Na2B407 4 H202 applied and based on coated sodium percar-bonate. The a stability of the coated sodium percar-bonate added to a commercial zeolite-cont~;n;ng detergent tower powder (Persil Supra TP) - 15 parts by weight of coated sodium percarbonate and 85 parts by weight of tower powder - during storage of the mixture under humid conditions in detergent packs is shown in the Table.
Example 2 Sodium percarbonate (according to Example 1) was sprayed with a perborax (Na2B407 4 H202)-containing solution and simultaneously dried in a fluidized bed dryer.
The solution was prepared by dissolving borax in 19.5% by weight H202 solution. Content of Na2B407 4 H202 31.2~ by weight; atomic ratio of boron to active oxygen 1:1. The solution was sprayed onto the percarbonate through a two-component nozzle at a fluidized bed temper-ature of 50-C (entry temperature of the drying air llO-C). The quantity sprayed corresponded to 5 parts by weight of perborax per 100 parts by weight of sodium percarbonate; O.content of the coated sodium percarbonate 14.2% by weight. The a stability of the coated sodium percarbonate added to a detergent powder is shown in the Table (tower powder and mixing ratio as in Example 1).
Example 3 Example 2 was repeated with the difference that the spray solution contained perborax with the formula Na2B407 2 H202; content 28.7% by weight; atomic ratio of boron to active oxygen 1:1.
Quantity of coating 5% by weight, based on sodium percarbonate. a content of the coated sodium percar-bonate 14.0% by weight. The a stability in a detergent tower powder is again shown in the Table (tower powder and mixing ratio as in Example 1).
Example 4 Centrifuge-moist sodium percarbonate - prepared by reaction of soda with hydrogen peroxide in aqueous phase in the presence of sodium chloride and sodium hexameta-phosphate and crystallization - was aftertreated in the centrifuge by washing with a perborax solution (33% by weight, based on Na2B407 4 H202) after removal of the mother liquor and subsequently dried in a fluidized bed dryer. The quantity of Na2B407 4 H202 applied corre-sponded to 2.5% by weight, based on sodium percarbonate.
The boron content was approximately 0.3~ by weight. The .
-a content of the coated percarbonate was 14.2% by weight.
The storage stability is shown in the Table.
Comparison Example ~
Sodium percarbonate was coated with 5% by weight of orthoboric acid, based on sodium percarbonate, by the process according to DE-PS 28 00 916 (see Example A6 of this document). a content of the coated sodium percar-bonate 13.4% by weight; boron content, based on coated sodium percarbonate, 0.83% by weight. The stability data during storage in the detergent mixture are shown in the Table.
Comparison Example 2 Sodium percarbonate was sprayed with an a~ueous borax solution (concentration 35% by weight) in a mixer (as in Example 1), the quantity of borax sprayed on amounting to 5 parts by weight per 100 parts by weight of sodium percarbonate. The material was then dried at 70C.
a content 13.5% by weight; boron content of the coated percarbonate 0.55% by weight, calculated from the borax applied on the assumption that borax was converted into Na2B407 5 H20 during drying.
Comparison Example 3 Sodium percarbonate was coated with sodium perborate and waterglass in accordance with DE-PS 28 10 379. The quantity of coating corresponded to 6% by weight of sodium perborate monohydrate and 1% by weight of water-glass. a content of the coated sodium percarbonate 14.3%
by weight;= boron content of the coated sodium percar-bonate (calculated from the quantity of NaB02 H202 applied) 0.62% by weight. The stability data in a detergent composition are shown in the Table.
To evaluate stability, coated sodium percarbonate of the Examples and Comparison Examples was stored in admixture with a commercial phosphate-free but zeolite-cont~;n;ng-detergent tower powder (Persil Supra TP) -mixing ratio 15:85 - in sealed detergent packs (0.4 1) ~ placed in a climatic chamber at a constant 30C/80%
relative humidity. The results of the active oxygen measurements of the mixtures carried out in the usual way at the beginn;ng and after storage for 2, 4 and 8 weeks are shown in the Table. For substantially the same boron content, sodium percarbonate particles coated in accord-ance with the invention show a higher stability in storage than the sodium percarbonate particles coated with boric acid, borax or perborate monohydrate.
~n x U --~ .. . .
~ ~o o ~ ~1 ~1 o -.C .
~ In ~ ~- ~ ~o o o ~
o oo a~ o _ _ C ~ ~
~Q i o I`
R
t, ~
R ~
~ J
--~ ~ er ~ o ~ ~ U~ ~
R ~1 ~q ~ 0 0 0 J ~
~ O ~ o o o o o o o wX V ~ r o~
R ~ o d~ ~ ~
E~m o ~n v ~J N ~1 N O
~ O
'_ ~ ~ ~ ~ ~ 0 ~1 ~ ~
R a:~ ~ m~
u,~-- zu~ z~ Zu. z~ m~ z~ z~O
~ o ,1 ,I h ~1 ~7 X O O X
Claims (10)
1. Coated sodium percarbonate particles consisting of a core of, essentially, sodium percarbonate and a coating containing at least one peroxygen-containing boron compound, characterized in that one or more reaction products from the reaction of a dialkali metal tetra-borate or alkali metal pentaborate with aqueous hydrogen peroxide are present as the peroxygen-containing boron compound.
2. Coated sodium percarbonate particles as claimed in claim 1, characterized in that the peroxygen-containing boron compound in the coating is a perborax with the general formula Na2B4O7 n H2O2 m H2O, where n is an integer of 1 to 4 and preferably 2 to 4 and m is an integer of 0 to 9 and preferably 0 to 2.
3. Coated sodium percarbonate particles as claimed in claim 1 or 2, characterized in that the quantity of coating, based on sodium percarbonate, makes up 1 to 10%
by weight and preferably 2 to 6% by weight.
by weight and preferably 2 to 6% by weight.
4. Coated sodium percarbonate particles as claimed in any of claims 1 to 3, characterized in that the coating consists of more than 50% by weight and preferably more than 70% by weight of the reaction products of hydrogen peroxide with a tetraborate or pentaborate and less than 50% by weight and preferably less than 30% by weight of other stabilizing compounds.
5. A process for the production of coated sodium percarbonate particles consisting of a core of, essen-tially, sodium percarbonate and a coating of one or more coating components, including at least one peroxygen-containing boron compound, by application of at least one peroxygen-containing boron compound and, if required, other coating components, preferably using an aqueous solution containing the coating components, to particles consisting essentially of sodium percarbonate and, if necessary, drying of the moist particles, characterized in that one or more reaction products from the reaction of a dialkali metal tetraborate or alkali metal penta-borate with aqueous hydrogen peroxide is used as the peroxygen-containing boron compound.
6. A process as claimed in claim 5, characterized in that the reaction products mentioned are used in the form of an aqueous solution, preferably of the reaction mixture, the solution mentioned containing boron and active oxygen in an atomic ratio of 1:0.2 to 1:1.5, preferably 1:0.5 to 1:1.25 and more preferably 1:sub-stantially 1.
7. A process as claimed in claim 5 or 6, characterized in that the solution to be applied contains a perborax with the general formula Na2B4O7 n H2O2, where n is an integer of 1 to 4 and preferably 2 to 4.
8. A process as claimed in any of claims 5 to 7, characterized in that the solution to be applied contains 20 to 50% by weight and more particularly 25 to 40% by weight of perborax with the general formula Na2B4O7 n H2O2, where n is an integer of 2 to 4, more particularly 4.
9. A process as claimed in any of claims 5 to 8, characterized in that an aqueous solution containing the peroxygen-containing boron compound is sprayed onto particles consisting essentially of sodium percarbonate either in a mixer or in a fluidized bed dryer and the resulting moist particles are simultaneously or subse-quently dried at 30 to 90°C and preferably at 50 to 80°C.
10. Detergent, cleaning and bleaching compositions containing coated sodium percarbonate particles according to any of claims 1 to 3 or obtained by the process claimed in claims 4 to 9.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP4311944.1 | 1993-04-10 | ||
DE4311944A DE4311944A1 (en) | 1993-04-10 | 1993-04-10 | Coated sodium percarbonate particles, process for their preparation and detergent, cleaning and bleaching compositions containing them |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2159991A1 true CA2159991A1 (en) | 1994-10-27 |
Family
ID=6485306
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002159991A Abandoned CA2159991A1 (en) | 1993-04-10 | 1994-02-28 | Encapsulated sodium percarbonate particles, method of producing them, and washing-agent, cleaning-agent and bleaching-agent compositions containing them |
Country Status (17)
Country | Link |
---|---|
US (1) | US5658873A (en) |
EP (1) | EP0693039B1 (en) |
JP (1) | JP3599737B2 (en) |
KR (1) | KR100308473B1 (en) |
CN (1) | CN1120832A (en) |
AT (1) | ATE156096T1 (en) |
AU (1) | AU6207894A (en) |
CA (1) | CA2159991A1 (en) |
CZ (1) | CZ249895A3 (en) |
DE (2) | DE4311944A1 (en) |
ES (1) | ES2106515T3 (en) |
FI (1) | FI954808A0 (en) |
PL (1) | PL173925B1 (en) |
SI (1) | SI9400166A (en) |
TR (1) | TR27402A (en) |
TW (1) | TW265320B (en) |
WO (1) | WO1994024044A1 (en) |
Families Citing this family (540)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
US8153602B1 (en) | 1991-11-19 | 2012-04-10 | Isis Pharmaceuticals, Inc. | Composition and methods for the pulmonary delivery of nucleic acids |
EP0728139B1 (en) | 1993-09-03 | 2003-08-13 | Isis Pharmaceuticals, Inc. | Amine-derivatized nucleosides and oligonucleosides |
DE4439069A1 (en) * | 1994-11-02 | 1996-05-09 | Degussa | Percarbonate containing detergent, bleach and detergent composition |
DE19629381A1 (en) * | 1996-07-20 | 1998-01-22 | Eilenburger Elektrolyse & Umwelttechnik Gmbh | Sodium peroxo:di:sulphate and sodium hydroxide production by electrolysis |
DE19544293C2 (en) * | 1995-11-28 | 1998-01-29 | Degussa | Encased sodium percarbonate particles and their use |
DE19600018A1 (en) | 1996-01-03 | 1997-07-10 | Henkel Kgaa | Detergent with certain oxidized oligosaccharides |
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
US20030044941A1 (en) | 1996-06-06 | 2003-03-06 | Crooke Stanley T. | Human RNase III and compositions and uses thereof |
US6639062B2 (en) | 1997-02-14 | 2003-10-28 | Isis Pharmaceuticals, Inc. | Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom |
EP1012331B1 (en) | 1997-07-01 | 2006-03-29 | Isis Pharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
FR2768140B1 (en) * | 1997-09-05 | 1999-10-08 | Atochem Elf Sa | STABLE SUPERSATURATED SODIUM PERBORATE SOLUTION AND ITS APPLICATION IN THE MANUFACTURE OF STABILIZED SODIUM PERCARBONATE PARTICLES |
US20040186071A1 (en) | 1998-04-13 | 2004-09-23 | Bennett C. Frank | Antisense modulation of CD40 expression |
EP1080103A4 (en) | 1998-05-21 | 2003-07-02 | Isis Pharmaceuticals Inc | Compositions and methods for non-parenteral delivery of oligonucleotides |
AU753270B2 (en) | 1998-05-21 | 2002-10-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for topical delivery of oligonucleotides |
US6335439B1 (en) | 1998-06-11 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Method of preparing phosphoramidites |
US6225293B1 (en) | 1998-09-02 | 2001-05-01 | Isis Pharmaceuticals, Inc. | Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations |
WO2000017309A1 (en) * | 1998-09-23 | 2000-03-30 | The Procter & Gamble Company | Coated perborate bleach and compositions containing the same |
US6077709A (en) | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
US6300320B1 (en) | 1999-01-05 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Modulation of c-jun using inhibitors of protein kinase C |
US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
US6147200A (en) * | 1999-08-19 | 2000-11-14 | Isis Pharmaceuticals, Inc. | 2'-O-acetamido modified monomers and oligomers |
US6617442B1 (en) * | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
US7332275B2 (en) | 1999-10-13 | 2008-02-19 | Sequenom, Inc. | Methods for detecting methylated nucleotides |
US20020055479A1 (en) | 2000-01-18 | 2002-05-09 | Cowsert Lex M. | Antisense modulation of PTP1B expression |
US6261840B1 (en) | 2000-01-18 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
EP1127840A1 (en) * | 2000-02-21 | 2001-08-29 | SOLVAY & Cie (Société Anonyme) | Process for preparing coated alkali metal percarbonate, coated alkaki metal percarbonate obtainable by this process, its use in detergent compositions, and detergent compositions containing it |
DE60140864D1 (en) * | 2000-04-13 | 2010-02-04 | Thomas N Wight | THERAPEUTIC SUMMARIES AND METHOD FOR MODULATING V3, AN ISOFORM FROM VERSICAN |
KR100366556B1 (en) | 2000-04-26 | 2003-01-09 | 동양화학공업주식회사 | Granular coated sodium percarbonate and process for preparing them |
US6680172B1 (en) | 2000-05-16 | 2004-01-20 | Regents Of The University Of Michigan | Treatments and markers for cancers of the central nervous system |
US6958214B2 (en) | 2000-07-10 | 2005-10-25 | Sequenom, Inc. | Polymorphic kinase anchor proteins and nucleic acids encoding the same |
US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
EP2336166A1 (en) | 2000-10-12 | 2011-06-22 | University Of Rochester | Compositions that inhibit proliferation of cancer cells |
US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US6573051B2 (en) * | 2001-03-09 | 2003-06-03 | Molecular Staging, Inc. | Open circle probes with intramolecular stem structures |
ES2328796T3 (en) | 2001-03-14 | 2009-11-18 | Myriad Genetics, Inc. | TSG101-GAG INTERACTION AND USE OF THE SAME. |
US7803915B2 (en) | 2001-06-20 | 2010-09-28 | Genentech, Inc. | Antibody compositions for the diagnosis and treatment of tumor |
CA2633171C (en) | 2001-06-20 | 2012-11-20 | Genentech, Inc. | Antibodies against tumor-associated antigenic target (tat) polypeptides |
AU2002315393A1 (en) | 2001-06-21 | 2003-01-08 | Isis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
US6964950B2 (en) | 2001-07-25 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of C-reactive protein expression |
US7425545B2 (en) | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
US20030096772A1 (en) | 2001-07-30 | 2003-05-22 | Crooke Rosanne M. | Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression |
US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
US7227014B2 (en) | 2001-08-07 | 2007-06-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
DE60238143D1 (en) | 2001-09-18 | 2010-12-09 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS OF TUMORS |
US6750019B2 (en) | 2001-10-09 | 2004-06-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of insulin-like growth factor binding protein 5 expression |
NZ577565A (en) | 2001-10-09 | 2010-10-29 | Isis Pharmaceuticals Inc | Antisense modulation of insulin-like growth factor binding protein 5 expressions |
US20030170678A1 (en) * | 2001-10-25 | 2003-09-11 | Neurogenetics, Inc. | Genetic markers for Alzheimer's disease and methods using the same |
US6965025B2 (en) | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
WO2003057160A2 (en) | 2002-01-02 | 2003-07-17 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US7169916B2 (en) * | 2002-04-01 | 2007-01-30 | Isis Pharmaceuticals, Inc. | Chloral-free DCA in oligonucleotide synthesis |
MXPA04010092A (en) | 2002-04-16 | 2004-12-13 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor. |
US7199107B2 (en) | 2002-05-23 | 2007-04-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of kinesin-like 1 expression |
AU2003276131A1 (en) * | 2002-06-18 | 2003-12-31 | Epigenesis Pharmaceuticals, Inc. | A dry powder oligonucleotide formulation, preparation and its uses |
US20050287648A1 (en) | 2002-08-05 | 2005-12-29 | University Of Rochester | Protein Transducing Domain/Deaminase Chimeric Proteins, Related Compounds, and Uses Thereof |
CN1694959B (en) | 2002-09-13 | 2013-09-18 | 雷普利瑟公司 | Non-sequence complementary antiviral oligonucleotides |
EP1546170A4 (en) * | 2002-09-20 | 2007-08-29 | Univ Yale | Riboswitches, methods for their use, and compositions for use with riboswitches |
EP1549767A4 (en) | 2002-09-26 | 2006-06-07 | Amgen Inc | Modulation of forkhead box o1a expression |
CA2504929C (en) | 2002-11-05 | 2014-07-22 | Charles Allerson | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
US9150605B2 (en) * | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
CA2504720C (en) | 2002-11-05 | 2013-12-24 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
US9150606B2 (en) | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
ES2420914T3 (en) | 2002-11-13 | 2013-08-27 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
EP2336318B1 (en) | 2002-11-13 | 2013-04-24 | Genzyme Corporation | Antisense modulation of apolipoprotein b expression |
US7754450B2 (en) | 2002-11-15 | 2010-07-13 | Morphotek, Inc. | Methods of generating high-production of antibodies from hybridomas created by in vitro immunization |
JP4915980B2 (en) | 2002-11-15 | 2012-04-11 | エムユーエスシー ファウンデーション フォー リサーチ デベロップメント | Complement receptor 2 targeted complement regulator |
EP1624753B1 (en) | 2002-11-21 | 2012-01-25 | The University of Utah Research Foundation | Purinergic modulation of smell |
US7144999B2 (en) | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
US20040121338A1 (en) * | 2002-12-19 | 2004-06-24 | Alsmadi Osama A. | Real-time detection of rolling circle amplification products |
US9487823B2 (en) | 2002-12-20 | 2016-11-08 | Qiagen Gmbh | Nucleic acid amplification |
WO2004058987A2 (en) | 2002-12-20 | 2004-07-15 | Qiagen Gmbh | Nucleic acid amplification |
ES2400033T3 (en) | 2003-02-11 | 2013-04-05 | Antisense Therapeutics Ltd | Modulation of insulin-like growth factor I receptor expression |
US7002006B2 (en) * | 2003-02-12 | 2006-02-21 | Isis Pharmaceuticals, Inc. | Protection of nucleosides |
US7803781B2 (en) | 2003-02-28 | 2010-09-28 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
US20040185559A1 (en) | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
US8043834B2 (en) | 2003-03-31 | 2011-10-25 | Qiagen Gmbh | Universal reagents for rolling circle amplification and methods of use |
US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
US7399853B2 (en) | 2003-04-28 | 2008-07-15 | Isis Pharmaceuticals | Modulation of glucagon receptor expression |
BRPI0410886A (en) | 2003-06-03 | 2006-07-04 | Isis Pharmaceuticals Inc | double stranded compound, pharmaceutical composition, pharmaceutically acceptable salt, methods of modifying human survivin-encoding nucleic acid, inhibiting suvivin expression in cells or tissues, and treating a condition associated with suvivin expression or overexpression, and single stranded RNA oligonucleotide |
EP1633770B1 (en) | 2003-06-13 | 2015-04-29 | Alnylam Europe AG | Double-stranded ribonucleic acid with increased effectiveness in an organism |
US7790691B2 (en) | 2003-06-20 | 2010-09-07 | Isis Pharmaceuticals, Inc. | Double stranded compositions comprising a 3′-endo modified strand for use in gene modulation |
CA2533701A1 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
US20050053981A1 (en) | 2003-09-09 | 2005-03-10 | Swayze Eric E. | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini |
US7425544B2 (en) | 2003-09-18 | 2008-09-16 | Eli Lilly And Company | Modulation of eIF4E expression |
WO2005027962A1 (en) | 2003-09-18 | 2005-03-31 | Isis Pharmaceuticals, Inc. | 4’-thionucleosides and oligomeric compounds |
US20050191653A1 (en) | 2003-11-03 | 2005-09-01 | Freier Susan M. | Modulation of SGLT2 expression |
EP1689432B1 (en) | 2003-11-17 | 2009-12-30 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
WO2005071080A2 (en) | 2004-01-20 | 2005-08-04 | Isis Pharmaceuticals, Inc. | Modulation of glucocorticoid receptor expression |
US8778900B2 (en) * | 2004-01-22 | 2014-07-15 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP1 expression |
US7468431B2 (en) | 2004-01-22 | 2008-12-23 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP2 expression |
US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
US8790919B2 (en) | 2004-03-15 | 2014-07-29 | Isis Pharmaceuticals, Inc. | Compositions and methods for optimizing cleavage of RNA by RNase H |
US20050267300A1 (en) | 2004-04-05 | 2005-12-01 | Muthiah Manoharan | Processes and reagents for oligonucleotide synthesis and purification |
US20050244869A1 (en) | 2004-04-05 | 2005-11-03 | Brown-Driver Vickie L | Modulation of transthyretin expression |
AU2005323437B2 (en) | 2004-04-30 | 2011-10-06 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a C5-modified pyrimidine |
EP3225633B1 (en) | 2004-05-21 | 2020-03-25 | The UAB Research Foundation | Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof |
US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
US7427675B2 (en) * | 2004-08-23 | 2008-09-23 | Isis Pharmaceuticals, Inc. | Compounds and methods for the characterization of oligonucleotides |
US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
WO2006032144A1 (en) | 2004-09-23 | 2006-03-30 | Arc Pharmaceuticals, Inc. | Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using fucans from various echinoderm sources |
JP2008516991A (en) | 2004-10-20 | 2008-05-22 | アンチセンス セラピューティクス リミテッド | Antisense regulation of integrin α4 expression |
US20060105937A1 (en) * | 2004-11-15 | 2006-05-18 | Melani Hardt Duran | Aqueous cleaning composition |
WO2006063031A2 (en) * | 2004-12-06 | 2006-06-15 | Haplomics | Allelic variants of human factor viii |
CN101175769A (en) | 2005-03-10 | 2008-05-07 | 健泰科生物技术公司 | Methods and compositions for modulating vascular integrity |
US8309303B2 (en) | 2005-04-01 | 2012-11-13 | Qiagen Gmbh | Reverse transcription and amplification of RNA with simultaneous degradation of DNA |
GB0508622D0 (en) * | 2005-04-28 | 2005-06-08 | Probe Ind Ltd | Method for treating effluent |
EP1891141B1 (en) | 2005-05-31 | 2016-11-16 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Triblock copolymers for cytoplasmic delivery of gene-based drugs |
US20090209621A1 (en) | 2005-06-03 | 2009-08-20 | The Johns Hopkins University | Compositions and methods for decreasing microrna expression for the treatment of neoplasia |
WO2006138145A1 (en) | 2005-06-14 | 2006-12-28 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
US7776532B2 (en) | 2005-08-11 | 2010-08-17 | Synthetic Genomics, Inc. | Method for in vitro recombination |
JP2009504168A (en) | 2005-08-17 | 2009-02-05 | メディクシス エス.エー. | Composition and method for confirming CK19 expression |
WO2007027775A2 (en) | 2005-08-29 | 2007-03-08 | Isis Pharmaceuticals, Inc. | Methods for use in modulating mir-122a |
US20090203893A1 (en) | 2005-08-29 | 2009-08-13 | Regulus Therapeutics, Llc | Antisense compounds having enhanced anti-microrna activity |
EP1762627A1 (en) | 2005-09-09 | 2007-03-14 | Qiagen GmbH | Method for the activation of a nucleic acid for performing a polymerase reaction |
US8080534B2 (en) | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
EP2392645A1 (en) | 2005-10-14 | 2011-12-07 | MUSC Foundation For Research Development | Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy |
JP5111385B2 (en) * | 2005-10-28 | 2013-01-09 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | Composition and method for suppressing expression of huntingtin gene |
CA2626584A1 (en) * | 2005-11-04 | 2007-05-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of nav1.8 gene |
AU2006311730B2 (en) | 2005-11-09 | 2010-12-02 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Factor V Leiden mutant gene |
JP2009516710A (en) | 2005-11-21 | 2009-04-23 | アイシス ファーマシューティカルズ, インコーポレーテッド | Modulating the expression of eIF4E-BP2 |
JP2009524411A (en) * | 2005-12-21 | 2009-07-02 | イェール ユニバーシティー | Methods and compositions related to the regulation of riboswitches |
JP5713377B2 (en) | 2005-12-28 | 2015-05-07 | ザ スクリプス リサーチ インスティテュート | Natural antisense and non-coding RNA transcripts as drug targets |
EP2422819B1 (en) | 2006-01-26 | 2017-03-01 | Ionis Pharmaceuticals, Inc. | Compositions and their uses directed to Huntingtin |
EP2388328A1 (en) | 2006-01-27 | 2011-11-23 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of micrornas |
ES2516815T3 (en) | 2006-01-27 | 2014-10-31 | Isis Pharmaceuticals, Inc. | Analogs of bicyclic nucleic acids modified at position 6 |
EP2527354A1 (en) | 2006-03-31 | 2012-11-28 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Eg5 gene |
MX2008014005A (en) | 2006-05-03 | 2009-01-27 | Baltic Technology Dev Ltd | Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease. |
EP2505650A1 (en) | 2006-05-05 | 2012-10-03 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of PCSK9 |
US8586554B2 (en) | 2006-05-05 | 2013-11-19 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of PTP1B |
DK2066684T3 (en) * | 2006-05-11 | 2012-10-22 | Isis Pharmaceuticals Inc | 5'-Modified Bicyclic Nucleic Acid Analogs |
US7666854B2 (en) * | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
CA2652770A1 (en) | 2006-05-19 | 2007-11-29 | Alnylam Pharmaceuticals, Inc. | Rnai modulation of aha and therapeutic uses thereof |
WO2007137220A2 (en) | 2006-05-22 | 2007-11-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of ikk-b gene |
US9506056B2 (en) | 2006-06-08 | 2016-11-29 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
US8198253B2 (en) | 2006-07-19 | 2012-06-12 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to HBXIP |
US8101585B2 (en) * | 2006-08-04 | 2012-01-24 | Isis Pharmaceuticals, Inc. | Compositions and methods for the modulation of JNK proteins |
US20100137440A1 (en) * | 2006-09-11 | 2010-06-03 | Yale University | Lysine riboswitches, structure-based compound design with lysine riboswitches, and methods and compositions for use of and with lysine riboswitches |
US7947487B2 (en) | 2006-10-05 | 2011-05-24 | Massachusetts Institute Of Technology | Multifunctional encoded particles for high-throughput analysis |
ES2526295T5 (en) | 2006-10-18 | 2021-05-04 | Ionis Pharmaceuticals Inc | Antisense compounds |
US8999317B2 (en) | 2006-11-01 | 2015-04-07 | University Of Rochester | Methods and compositions related to the structure and function of APOBEC3G |
US8084437B2 (en) * | 2006-11-27 | 2011-12-27 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
US8093222B2 (en) | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
KR20090089462A (en) | 2006-12-11 | 2009-08-21 | 유니버시티 오브 유타 리써치 파운데이션 | Compositions and methods for treating pathologic angiogenesis and vascular permeability |
US20100129358A1 (en) | 2006-12-22 | 2010-05-27 | University Of Utah Research Foundation | Method of detecting ocular diseases and pathologic conditions and treatment of same |
KR101488800B1 (en) | 2007-02-09 | 2015-02-04 | 노오쓰웨스턴 유니버시티 | Particles for detecting intracellular targets |
JP2010520749A (en) * | 2007-02-27 | 2010-06-17 | ノースウェスタン ユニバーシティ | Binding molecules to nanoparticles |
CN101801185A (en) | 2007-03-22 | 2010-08-11 | 耶鲁大学 | Methods and compositions related to riboswitches that control alternative splicing |
AU2008232891B2 (en) | 2007-03-29 | 2012-01-12 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a gene from the Ebola |
US20110091377A1 (en) | 2007-05-11 | 2011-04-21 | The Johns Hopkins University | Biomarkers for melanoma |
CA2687684A1 (en) * | 2007-05-29 | 2008-12-11 | Yale University | Methods and compositions related to riboswitches that control alternative splicing and rna processing |
SG174103A1 (en) * | 2007-05-29 | 2011-09-29 | Univ Yale | Riboswitches and methods and compositions for use of and with riboswitches |
AU2008260277C1 (en) | 2007-05-30 | 2014-04-17 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
US7807372B2 (en) * | 2007-06-04 | 2010-10-05 | Northwestern University | Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay |
DK2173760T4 (en) | 2007-06-08 | 2016-02-08 | Isis Pharmaceuticals Inc | Carbocyclic bicyclic nukleinsyreanaloge |
EP2176280B2 (en) * | 2007-07-05 | 2015-06-24 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
US8088904B2 (en) | 2007-08-15 | 2012-01-03 | Isis Pharmaceuticals, Inc. | Tetrahydropyran nucleic acid analogs |
JP2010537638A (en) | 2007-08-28 | 2010-12-09 | ユーエービー リサーチ ファウンデーション | Synthetic apolipoprotein E mimetic polypeptides and methods of use |
JP2010538005A (en) | 2007-08-28 | 2010-12-09 | ユーエービー リサーチ ファウンデーション | Synthetic apolipoprotein E mimetic polypeptides and methods of use |
WO2009039466A1 (en) | 2007-09-20 | 2009-03-26 | Vanderbilt University | Free solution measurement of molecular interactions by backscattering interferometry |
WO2009039442A1 (en) | 2007-09-21 | 2009-03-26 | California Institute Of Technology | Nfia in glial fate determination, glioma therapy and astrocytoma treatment |
EP2222851B1 (en) | 2007-11-20 | 2017-06-28 | Ionis Pharmaceuticals, Inc. | Modulation of cd40 expression |
JP5530933B2 (en) | 2007-12-10 | 2014-06-25 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | Compositions and methods for inhibiting factor VII gene expression |
WO2009086558A1 (en) | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
EA019531B1 (en) | 2008-03-05 | 2014-04-30 | Элнилэм Фармасьютикалз, Инк. | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES |
WO2009124238A1 (en) * | 2008-04-04 | 2009-10-08 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides |
WO2009124295A2 (en) * | 2008-04-04 | 2009-10-08 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity |
JP5685182B2 (en) | 2008-04-18 | 2015-03-18 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | Microsphere-based composition for preventing and / or reversing primary autoimmune diabetes |
CN101270232B (en) * | 2008-04-22 | 2011-04-20 | 浙江时代金科过氧化物有限公司 | Method for preparing particle type coating sodium percarbonate |
EP2280995A2 (en) * | 2008-04-29 | 2011-02-09 | Wyeth LLC | Methods for treating inflammation |
EP2297322A1 (en) | 2008-06-04 | 2011-03-23 | The Board of Regents of The University of Texas System | Modulation of gene expression through endogenous small rna targeting of gene promoters |
AU2009276763B2 (en) | 2008-07-29 | 2015-07-16 | The Board Of Regents Of The University Of Texas Sytem | Selective inhibition of polyglutamine protein expression |
EP2334319B1 (en) | 2008-08-25 | 2017-12-06 | Excaliard Pharmaceuticals, Inc. | Method for reducing scarring during wound healing using antisense compounds directed to ctgf |
AU2009275387B2 (en) | 2008-08-25 | 2010-07-08 | Excaliard Pharmaceuticals, Inc. | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
EP2331690B1 (en) | 2008-09-02 | 2016-01-13 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of mutant egfr gene |
US20100075883A1 (en) * | 2008-09-24 | 2010-03-25 | Ecolab Inc. | Granular cleaning and disinfecting composition |
US8501805B2 (en) * | 2008-09-24 | 2013-08-06 | Isis Pharmaceuticals, Inc. | Substituted alpha-L-bicyclic nucleosides |
EP2334793B1 (en) | 2008-09-25 | 2016-04-06 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of serum amyloid a gene |
EP2743265B1 (en) | 2008-10-09 | 2017-03-15 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
IL302142B1 (en) | 2008-10-20 | 2024-03-01 | Alnylam Pharmaceuticals Inc | Compositions and Methods for Inhabiting Expression of TRANSTHYRETIN |
EP2447274B1 (en) | 2008-10-24 | 2017-10-04 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
DK2365803T3 (en) | 2008-11-24 | 2018-01-22 | Univ Northwestern | POLYVALENT RNA NANOPARTICLE COMPOSITIONS |
CN102317458B (en) | 2008-12-04 | 2018-01-02 | 库尔纳公司 | Pass through treatment of the suppression of erythropoietin(EPO) (EPO) natural antisense transcript to EPO relevant diseases |
EP2370580B1 (en) | 2008-12-04 | 2019-09-11 | CuRNA, Inc. | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1 |
WO2010065787A2 (en) | 2008-12-04 | 2010-06-10 | Curna, Inc. | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
AU2009324534B2 (en) | 2008-12-10 | 2015-07-30 | Alnylam Pharmaceuticals, Inc. | GNAQ targeted dsRNA compositions and methods for inhibiting expression |
US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
KR101546673B1 (en) * | 2009-01-15 | 2015-08-25 | 삼성전자주식회사 | Toner for electrophotographic and process for preparing the same |
WO2010088537A2 (en) | 2009-01-29 | 2010-08-05 | Alnylam Pharmaceuticals, Inc. | Improved lipid formulation |
US8536320B2 (en) | 2009-02-06 | 2013-09-17 | Isis Pharmaceuticals, Inc. | Tetrahydropyran nucleic acid analogs |
WO2010091308A2 (en) | 2009-02-06 | 2010-08-12 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
JP5766126B2 (en) | 2009-02-12 | 2015-08-19 | クルナ・インコーポレーテッド | Treatment of brain-derived neurotrophic factor (BDNF) -related diseases by suppression of natural antisense transcripts against BDNF |
CA2752239C (en) | 2009-02-12 | 2021-03-30 | Opko Curna, Llc | Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf |
US20120041051A1 (en) | 2009-02-26 | 2012-02-16 | Kevin Fitzgerald | Compositions And Methods For Inhibiting Expression Of MIG-12 Gene |
EP2403946A4 (en) | 2009-03-04 | 2012-11-14 | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1 | |
US20100267806A1 (en) | 2009-03-12 | 2010-10-21 | David Bumcrot | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES |
CN102482677B (en) | 2009-03-16 | 2017-10-17 | 库尔纳公司 | Nuclear factor (red blood cell derives 2) sample 2 (NRF2) relevant disease is treated by suppressing NRF2 natural antisense transcript |
CN102549159B (en) | 2009-03-17 | 2016-08-10 | 库尔纳公司 | By suppressing to treat the disease that DLK1 is correlated with for the natural antisense transcript of δ sample 1 congener (DLK1) |
CA2757694C (en) | 2009-04-15 | 2020-10-06 | Northwestern University | Delivery of oligonucleotide-functionalized nanoparticles |
EP3248618A1 (en) | 2009-04-22 | 2017-11-29 | Massachusetts Institute Of Technology | Innate immune suppression enables repeated delivery of long rna molecules |
EP2421972A2 (en) | 2009-04-24 | 2012-02-29 | The Board of Regents of The University of Texas System | Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions |
DK2424987T3 (en) | 2009-05-01 | 2018-02-26 | Curna Inc | TREATMENT OF HEMOGLOBIN (HBF / HBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPTION TO HBF / HBG |
AU2010245933B2 (en) | 2009-05-05 | 2016-06-16 | Arbutus Biopharma Corporation | Methods of delivering oligonucleotides to immune cells |
NZ596186A (en) | 2009-05-05 | 2014-03-28 | Alnylam Pharmaceuticals Inc | Lipid compositions |
ES2609655T3 (en) | 2009-05-06 | 2017-04-21 | Curna, Inc. | Treatment of diseases related to tristetraproline (TTP) by inhibition of natural antisense transcript for TTP |
WO2010129799A2 (en) | 2009-05-06 | 2010-11-11 | Curna, Inc. | Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene |
WO2010132665A1 (en) | 2009-05-15 | 2010-11-18 | Yale University | Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches |
EP2432881B1 (en) | 2009-05-18 | 2017-11-15 | CuRNA, Inc. | Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor |
WO2010135695A2 (en) | 2009-05-22 | 2010-11-25 | Curna, Inc. | TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3 |
ES2618576T3 (en) | 2009-05-28 | 2017-06-21 | Curna, Inc. | Treatment of diseases related to an antiviral gene by inhibiting a natural antisense transcript to an antiviral gene |
HUE038796T2 (en) | 2009-06-10 | 2018-11-28 | Arbutus Biopharma Corp | Improved lipid formulation |
JP6128846B2 (en) | 2009-06-16 | 2017-05-17 | クルナ・インコーポレーテッド | Treatment of PON1 gene-related diseases by suppression of natural antisense transcripts against paraoxonase (PON1) |
WO2010148050A2 (en) | 2009-06-16 | 2010-12-23 | Curna, Inc. | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
CN106983768B (en) | 2009-06-17 | 2023-04-07 | 冷泉港实验室 | Compositions and methods for modulating SMN2 splicing in a subject |
WO2010151671A2 (en) | 2009-06-24 | 2010-12-29 | Curna, Inc. | Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
CA2765815A1 (en) | 2009-06-26 | 2010-12-29 | Opko Curna, Llc | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
CA2769665A1 (en) | 2009-08-05 | 2011-02-10 | Opko Curna, Llc | Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins) |
EP2464336A4 (en) | 2009-08-14 | 2013-11-20 | Alnylam Pharmaceuticals Inc | Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus |
WO2011022420A1 (en) | 2009-08-17 | 2011-02-24 | Yale University | Methylation biomarkers and methods of use |
KR101892760B1 (en) | 2009-08-25 | 2018-08-28 | 큐알엔에이, 인크. | Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap |
AU2010289400B2 (en) | 2009-09-02 | 2014-10-23 | Curis, Inc. | Mutant smoothened and methods of using the same |
CA2778442A1 (en) | 2009-10-22 | 2011-04-28 | Genentech, Inc. | Methods and compositions for modulating hepsin activation of macrophage-stimulating protein |
JP6147502B2 (en) | 2009-10-27 | 2017-06-14 | スウィフト バイオサイエンシーズ, インコーポレイテッド | Polynucleotide primers and probes |
US9376690B2 (en) | 2009-10-30 | 2016-06-28 | Northwestern University | Templated nanoconjugates |
WO2011053994A1 (en) | 2009-11-02 | 2011-05-05 | Alnylam Pharmaceuticals, Inc. | Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter |
KR20120102674A (en) | 2009-11-03 | 2012-09-18 | 유니버시티 오브 버지니아 페이턴트 파운데이션 | Versatile, visible method for detecting polymeric analytes |
CA2781469A1 (en) | 2009-11-23 | 2011-05-26 | Swift Biosciences, Inc. | Devices to extend single stranded target molecules |
CN102741294A (en) | 2009-11-30 | 2012-10-17 | 霍夫曼-拉罗奇有限公司 | Antibodies for treating and diagnosing tumors expressing SLC34A2 (TAT211 = SEQID 2) |
NO2513310T3 (en) | 2009-12-16 | 2018-03-31 | ||
US9068183B2 (en) | 2009-12-23 | 2015-06-30 | Curna, Inc. | Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2 |
CN102869776B (en) | 2009-12-23 | 2017-06-23 | 库尔纳公司 | HGF relevant diseases are treated by suppressing the natural antisense transcript of HGF (HGF) |
KR101853508B1 (en) | 2009-12-29 | 2018-06-20 | 큐알엔에이, 인크. | TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63 |
CA2785173A1 (en) | 2009-12-29 | 2011-07-28 | Curna, Inc. | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
US8946181B2 (en) | 2010-01-04 | 2015-02-03 | Curna, Inc. | Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8 |
RU2612161C2 (en) | 2010-01-06 | 2017-03-02 | Курна, Инк. | Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to pancreatic developmental gene |
WO2011085347A2 (en) | 2010-01-11 | 2011-07-14 | Opko Curna, Llc | Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg |
WO2011088076A2 (en) | 2010-01-12 | 2011-07-21 | Yale University | Structured rna motifs and compounds and methods for their use |
BR112012017483A2 (en) * | 2010-01-14 | 2019-09-24 | Haplomics Inc | prediction and reduction of alloimmunogenicity of protein therapeutics |
CN102782135A (en) | 2010-01-25 | 2012-11-14 | 库尔纳公司 | Treatment of RNase H1 related diseases by inhibition of natural antisense transcript to RNase H1 |
US9574191B2 (en) | 2010-02-03 | 2017-02-21 | The Board Of Regents Of The University Of Texas System | Selective inhibition of polyglutamine protein expression |
CA2824843A1 (en) | 2010-02-04 | 2011-08-11 | Ico Therapeutics Inc. | Dosing regimens for treating and preventing ocular disorders using c-raf antisense |
CA2790506A1 (en) | 2010-02-22 | 2011-08-25 | Curna, Inc. | Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1 |
WO2011105902A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-beta (c8-beta) and uses thereof |
WO2011105900A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-alpha (c8-alpha) and uses thereof |
WO2011105901A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 9 (c9) and uses thereof |
PE20130214A1 (en) | 2010-02-23 | 2013-03-11 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS |
WO2011112516A1 (en) | 2010-03-08 | 2011-09-15 | Ico Therapeutics Inc. | Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides |
WO2011113054A2 (en) | 2010-03-12 | 2011-09-15 | Aurasense Llc | Crosslinked polynucleotide structure |
AU2011235276B2 (en) | 2010-03-29 | 2015-09-03 | Alnylam Pharmaceuticals, Inc. | SiRNA therapy for transthyretin (TTR) related ocular amyloidosis |
TWI644675B (en) | 2010-04-09 | 2018-12-21 | 可娜公司 | Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21 |
US20110269194A1 (en) | 2010-04-20 | 2011-11-03 | Swift Biosciences, Inc. | Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment |
MX343559B (en) | 2010-04-29 | 2016-11-10 | Ionis Pharmaceuticals Inc | Modulation of transthyretin expression. |
CN107988228B (en) | 2010-05-03 | 2022-01-25 | 库尔纳公司 | Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to Sirtuin (SIRT) |
MX342239B (en) | 2010-05-03 | 2016-09-21 | Genentech Inc * | Compositions and methods for the diagnosis and treatment of tumor. |
TWI531370B (en) | 2010-05-14 | 2016-05-01 | 可娜公司 | Treatment of par4 related diseases by inhibition of natural antisense transcript to par4 |
US20130203045A1 (en) | 2010-05-26 | 2013-08-08 | University Of Virginia Patent Foundation | Method for detecting nucleic acids based on aggregate formation |
DK2576783T3 (en) | 2010-05-26 | 2018-03-12 | Curna Inc | TREATMENT OF ATONAL HOMOLOGY 1- (ATOH1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS AT ATOH1 |
EP2576579B1 (en) | 2010-06-02 | 2018-08-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods directed to treating liver fibrosis |
CA2802049C (en) | 2010-06-07 | 2018-07-10 | Firefly Bioworks, Inc. | Scanning multifunctional particles |
US9638632B2 (en) | 2010-06-11 | 2017-05-02 | Vanderbilt University | Multiplexed interferometric detection system and method |
WO2011163466A1 (en) | 2010-06-23 | 2011-12-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Regulation of skin pigmentation by neuregulin-1 (nrg-1) |
NO2593547T3 (en) | 2010-07-14 | 2018-04-14 | ||
US20130143955A1 (en) | 2010-08-09 | 2013-06-06 | Yale University | Cyclic di-GMP-II Riboswitches, Motifs, and Compounds, and Methods for Their Use |
WO2012047968A2 (en) | 2010-10-05 | 2012-04-12 | Genentech, Inc. | Mutant smoothened and methods of using the same |
RU2624048C2 (en) | 2010-10-06 | 2017-06-30 | Курна, Инк. | Treatment of diseases associated with the sialidase 4 (neu4) gene, by gene neu4 natural antisense transcript inhibition |
JP6049623B2 (en) | 2010-10-22 | 2016-12-21 | カッパーアールエヌエー,インコーポレイテッド | Treatment of IDUA-related diseases by inhibition of natural antisense transcripts to α-L-iduronidase (IDUA) |
KR101913232B1 (en) | 2010-10-27 | 2018-10-30 | 큐알엔에이, 인크. | Treatment of interferon-related developmental regulator 1(ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1 |
CN110123830A (en) | 2010-11-09 | 2019-08-16 | 阿尔尼拉姆医药品有限公司 | Composition and method for inhibiting the lipid of the expression of Eg5 and VEGF gene to prepare |
JP6071893B2 (en) | 2010-11-23 | 2017-02-01 | カッパーアールエヌエー,インコーポレイテッド | Treatment of NANOG-related diseases by inhibition of natural antisense transcripts to NANOG |
US9150926B2 (en) | 2010-12-06 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Diagnosis and treatment of adrenocortical tumors using human microRNA-483 |
US9127275B2 (en) | 2010-12-10 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of klf-1 and bcl11a genes |
US9193973B2 (en) | 2010-12-10 | 2015-11-24 | Alynylam Pharmaceuticals, Inc. | Compositions and methods for increasing erythropoietin (EPO) production |
EP2670404B1 (en) | 2011-02-02 | 2018-08-29 | The Trustees of Princeton University | Sirtuin modulators as virus production modulators |
MX365647B (en) | 2011-02-02 | 2019-06-10 | Excaliard Pharmaceuticals Inc | Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf). |
MY165507A (en) | 2011-02-03 | 2018-03-28 | Mirna Therapeutics Inc | Synthetic mimics of mir-34 |
EP2670849A1 (en) | 2011-02-03 | 2013-12-11 | Mirna Therapeutics, Inc. | Synthetic mimics of mir-124 |
EP3067421B1 (en) | 2011-02-08 | 2018-10-10 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
US9562853B2 (en) | 2011-02-22 | 2017-02-07 | Vanderbilt University | Nonaqueous backscattering interferometric methods |
KR102365961B1 (en) | 2011-03-29 | 2022-02-23 | 알닐람 파마슈티칼스 인코포레이티드 | Compositions and methods for inhibiting expression of tmprss6 gene |
EP2694660B1 (en) | 2011-04-03 | 2018-08-08 | The General Hospital Corporation | Efficient protein expression in vivo using modified rna (mod-rna) |
WO2012149154A1 (en) | 2011-04-26 | 2012-11-01 | Swift Biosciences, Inc. | Polynucleotide primers and probes |
WO2012151289A2 (en) | 2011-05-02 | 2012-11-08 | University Of Virginia Patent Foundation | Method and system to detect aggregate formation on a substrate |
WO2012151268A1 (en) | 2011-05-02 | 2012-11-08 | University Of Virginia Patent Foundation | Method and system for high throughput optical and label free detection of analytes |
CN103620036B (en) | 2011-06-09 | 2016-12-21 | 库尔纳公司 | FXN relevant disease is treated by the natural antisense transcript of suppression Frataxin (FXN) |
CA3191066A1 (en) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes |
AU2012272970A1 (en) | 2011-06-21 | 2014-02-06 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof |
EP2723351B1 (en) | 2011-06-21 | 2018-02-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of expression of protein c (proc) genes |
EP2723390B1 (en) | 2011-06-23 | 2017-12-27 | Alnylam Pharmaceuticals, Inc. | Serpina1 sirnas: compositions of matter and methods of treatment |
JP2014526887A (en) | 2011-08-01 | 2014-10-09 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | How to improve the success rate of hematopoietic stem cell transplantation |
EP4269584A3 (en) | 2011-08-11 | 2024-03-27 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
WO2013040499A1 (en) | 2011-09-14 | 2013-03-21 | Northwestern University | Nanoconjugates able to cross the blood-brain barrier |
US9580713B2 (en) | 2011-09-17 | 2017-02-28 | Yale University | Fluoride-responsive riboswitches, fluoride transporters, and methods of use |
RS57645B1 (en) | 2011-10-14 | 2018-11-30 | Hoffmann La Roche | Anti-htra1 antibodies and methods of use |
CA2859387A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
WO2013106358A1 (en) | 2012-01-10 | 2013-07-18 | Hussain M Mahmood | Method of treating hyperlipidemia and atherosclerosis with mir-30c |
JP6509723B2 (en) | 2012-03-13 | 2019-05-08 | スウィフト バイオサイエンシーズ, インコーポレイテッド | Methods and compositions for size-controlled homopolymeric tailing of substrate polynucleotides by nucleic acid polymerase |
ES2694592T3 (en) | 2012-03-15 | 2018-12-21 | Curna, Inc. | Treatment of diseases related to brain-derived neurotrophic factor (BDNF) by inhibition of the natural antisense transcript of BDNF |
US9610362B2 (en) | 2012-03-16 | 2017-04-04 | Valerion Therapeutics, Llc | Antisense conjugates for decreasing expression of DMPK |
AU2013243951A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
CN104411338A (en) | 2012-04-02 | 2015-03-11 | 现代治疗公司 | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US9133461B2 (en) | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
US9914922B2 (en) | 2012-04-20 | 2018-03-13 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
US9273949B2 (en) | 2012-05-11 | 2016-03-01 | Vanderbilt University | Backscattering interferometric methods |
US20140038182A1 (en) | 2012-07-17 | 2014-02-06 | Dna Logix, Inc. | Cooperative primers, probes, and applications thereof |
EP2897633B1 (en) | 2012-09-18 | 2020-01-01 | UTI Limited Partnership | Treatment of pain by inhibition of usp5 de-ubiquitinase |
US9695418B2 (en) | 2012-10-11 | 2017-07-04 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleosides and uses thereof |
AU2013337277B2 (en) | 2012-11-05 | 2018-03-08 | Foundation Medicine, Inc. | Novel NTRK1 fusion molecules and uses thereof |
JP6144355B2 (en) | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | Chemically modified mRNA |
WO2014089541A2 (en) | 2012-12-07 | 2014-06-12 | Haplomics, Inc. | Factor viii mutation repair and tolerance induction |
WO2014113089A2 (en) | 2013-01-17 | 2014-07-24 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
EP3939614A1 (en) | 2013-01-18 | 2022-01-19 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
US20150366890A1 (en) | 2013-02-25 | 2015-12-24 | Trustees Of Boston University | Compositions and methods for treating fungal infections |
US10398661B2 (en) | 2013-02-28 | 2019-09-03 | The Board Of Regents Of The University Of Texas System | Methods for classifying a cancer as susceptible to TMEPAI-directed therapies and treating such cancers |
WO2014159813A1 (en) | 2013-03-13 | 2014-10-02 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
PT2970974T (en) | 2013-03-14 | 2017-11-29 | Alnylam Pharmaceuticals Inc | Complement component c5 irna compositions and methods of use thereof |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
EP4286517A3 (en) | 2013-04-04 | 2024-03-13 | President and Fellows of Harvard College | Therapeutic uses of genome editing with crispr/cas systems |
US10590412B2 (en) | 2013-04-19 | 2020-03-17 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulation nucleic acids through nonsense mediated decay |
SG10201804472YA (en) | 2013-05-22 | 2018-07-30 | Alnylam Pharmaceuticals Inc | SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
SG11201510565TA (en) | 2013-05-22 | 2016-01-28 | Alnylam Pharmaceuticals Inc | Tmprss6 irna compositions and methods of use thereof |
EP3004396B1 (en) | 2013-06-06 | 2019-10-16 | The General Hospital Corporation | Compositions for the treatment of cancer |
ES2862125T3 (en) | 2013-06-13 | 2021-10-07 | Antisense Therapeutics Ltd | Combination therapy for acromegaly |
LT3019619T (en) | 2013-07-11 | 2021-12-10 | Modernatx, Inc. | Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use |
HUE048710T2 (en) | 2013-08-08 | 2020-08-28 | Scripps Research Inst | A method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides |
EP3041934A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
US10077444B2 (en) | 2013-10-02 | 2018-09-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the LECT2 gene |
EA201690675A1 (en) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | POLYNUCLEOTES ENCODING THE RECEPTOR OF LOW DENSITY LIPOPROTEINS |
LT3052628T (en) | 2013-10-04 | 2020-09-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the alas1 gene |
EP3055426B1 (en) | 2013-10-09 | 2019-06-19 | The United States of America as represented by The Secretary Department of Health and Human Services | Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma |
EP3060680B1 (en) | 2013-10-21 | 2019-02-27 | The General Hospital Corporation | Methods relating to circulating tumor cell clusters and the treatment of cancer |
WO2015066708A1 (en) | 2013-11-04 | 2015-05-07 | Northwestern University | Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (sna) |
US10182988B2 (en) | 2013-12-03 | 2019-01-22 | Northwestern University | Liposomal particles, methods of making same and uses thereof |
US10385388B2 (en) | 2013-12-06 | 2019-08-20 | Swift Biosciences, Inc. | Cleavable competitor polynucleotides |
CA2844640A1 (en) | 2013-12-06 | 2015-06-06 | The University Of British Columbia | Method for treatment of castration-resistant prostate cancer |
EP3798306A1 (en) | 2013-12-12 | 2021-03-31 | Alnylam Pharmaceuticals, Inc. | Complement component irna compositions and methods of use thereof |
US10900083B2 (en) | 2013-12-20 | 2021-01-26 | The General Hospital Corporation | Methods and assays relating to circulating tumor cells |
JP6736467B2 (en) | 2014-02-04 | 2020-08-05 | ジェネンテック, インコーポレイテッド | Smoothing mutant and method of using the same |
KR20230152154A (en) | 2014-02-11 | 2023-11-02 | 알닐람 파마슈티칼스 인코포레이티드 | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
EP3943607A1 (en) | 2014-04-09 | 2022-01-26 | The Scripps Research Institute | Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters |
MA39835A (en) | 2014-04-17 | 2017-02-22 | Biogen Ma Inc | Compositions and methods for modulation of smn2 splicing in a subject |
TW201607559A (en) | 2014-05-12 | 2016-03-01 | 阿尼拉製藥公司 | Methods and compositions for treating a SERPINC1-associated disorder |
SG10202104570TA (en) | 2014-05-22 | 2021-06-29 | Alnylam Pharmaceuticals Inc | Angiotensinogen (agt) irna compositions and methods of use thereof |
AU2015270925A1 (en) | 2014-06-02 | 2016-12-22 | Children's Medical Center Corporation | Methods and compositions for immunomodulation |
EP3155100B1 (en) | 2014-06-10 | 2021-12-22 | Erasmus University Medical Center Rotterdam | Antisense oligonucleotides useful in treatment of pompe disease |
WO2016011226A1 (en) | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
US9951327B1 (en) | 2014-07-17 | 2018-04-24 | Integrated Dna Technologies, Inc. | Efficient and rapid method for assembling and cloning double-stranded DNA fragments |
WO2016014846A1 (en) | 2014-07-23 | 2016-01-28 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of intrabodies |
JP7081923B2 (en) | 2014-07-31 | 2022-06-07 | ユーエイビー リサーチ ファンデーション | Higher effectiveness for removing apoE mimetic peptides and plasma cholesterol |
CA2958431A1 (en) | 2014-08-19 | 2016-02-25 | Northwestern University | Protein/oligonucleotide core-shell nanoparticle therapeutics |
WO2016033424A1 (en) | 2014-08-29 | 2016-03-03 | Genzyme Corporation | Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b |
ES2928500T3 (en) | 2014-08-29 | 2022-11-18 | Alnylam Pharmaceuticals Inc | Patisiran for use in the treatment of transthyretin-mediated amyloidosis |
EP4043567A1 (en) | 2014-08-29 | 2022-08-17 | Children's Medical Center Corporation | Methods and compositions for the treatment of cancer |
EP3191591A1 (en) | 2014-09-12 | 2017-07-19 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
EP3194597B1 (en) | 2014-09-18 | 2021-06-30 | The University Of British Columbia | Allele-specific therapy for huntington disease haplotypes |
JOP20200115A1 (en) | 2014-10-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | Compositions And Methods For Inhibition Of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression |
WO2016061487A1 (en) | 2014-10-17 | 2016-04-21 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof |
EP3904519A1 (en) | 2014-10-30 | 2021-11-03 | Genzyme Corporation | Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof |
JOP20200092A1 (en) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
MX2017006139A (en) | 2014-11-10 | 2017-11-16 | Glaxosmithkline Intelectual Property (No 2) Ltd | Long acting pharmaceutical compositions for hepatitis c. |
SG11201703646SA (en) | 2014-11-10 | 2017-06-29 | Glaxosmithkline Intellectual Property (No 2) Ltd | Combination long acting compositions and methods for hepatitis c |
WO2016081444A1 (en) | 2014-11-17 | 2016-05-26 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
CA2968531A1 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
US20160145547A1 (en) | 2014-11-25 | 2016-05-26 | Milliken & Company | Film-Encased Cleaning Composition |
EP3234141A4 (en) | 2014-12-18 | 2018-06-20 | Alnylam Pharmaceuticals, Inc. | Reversir tm compounds |
WO2016118812A1 (en) | 2015-01-23 | 2016-07-28 | Vanderbilt University | A robust interferometer and methods of using same |
CA2976445A1 (en) | 2015-02-13 | 2016-08-18 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
KR20180020125A (en) | 2015-03-27 | 2018-02-27 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Modified T cells and methods for their manufacture and use |
US10745702B2 (en) | 2015-04-08 | 2020-08-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the LECT2 gene |
EP3307316A1 (en) | 2015-06-12 | 2018-04-18 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
WO2016205323A1 (en) | 2015-06-18 | 2016-12-22 | Alnylam Pharmaceuticals, Inc. | Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof |
WO2016209862A1 (en) | 2015-06-23 | 2016-12-29 | Alnylam Pharmaceuticals, Inc. | Glucokinase (gck) irna compositions and methods of use thereof |
WO2017011286A1 (en) | 2015-07-10 | 2017-01-19 | Alnylam Pharmaceuticals, Inc. | Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof |
CA3205381A1 (en) | 2015-07-17 | 2017-01-26 | Alnylam Pharmaceuticals, Inc. | Multi-targeted single entity conjugates |
WO2017021961A1 (en) | 2015-08-04 | 2017-02-09 | Yeda Research And Development Co. Ltd. | Methods of screening for riboswitches and attenuators |
SG10202007937SA (en) | 2015-09-02 | 2020-09-29 | Alnylam Pharmaceuticals Inc | PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
PE20181009A1 (en) | 2015-10-30 | 2018-06-26 | Genentech Inc | ANTI-HtrA1 ANTIBODIES AND METHODS OF USE OF THEM |
ES2938883T3 (en) | 2015-11-05 | 2023-04-17 | Los Angeles Childrens Hospital | Oligo antisense for use in the treatment of acute myeloid leukemia |
US10993995B2 (en) | 2015-12-07 | 2021-05-04 | Erasmus University Medical Center Rotterdam | Enzymatic replacement therapy and antisense therapy for pompe disease |
US11761007B2 (en) | 2015-12-18 | 2023-09-19 | The Scripps Research Institute | Production of unnatural nucleotides using a CRISPR/Cas9 system |
US10627396B2 (en) | 2016-01-29 | 2020-04-21 | Vanderbilt University | Free-solution response function interferometry |
WO2017136558A1 (en) | 2016-02-04 | 2017-08-10 | Curis, Inc. | Mutant smoothened and methods of using the same |
MA45295A (en) | 2016-04-19 | 2019-02-27 | Alnylam Pharmaceuticals Inc | HIGH DENSITY LIPOPROTEIN BINDING PROTEIN (HDLBP / VIGILINE) RNA COMPOSITION AND METHODS FOR USING THEM |
US20190256845A1 (en) | 2016-06-10 | 2019-08-22 | Alnylam Pharmaceuticals, Inc. | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) |
HUE060123T2 (en) | 2016-06-24 | 2023-01-28 | Scripps Research Inst | Novel nucleoside triphosphate transporter and uses thereof |
CN109844103A (en) | 2016-07-21 | 2019-06-04 | 美克斯细胞有限公司 | Method and composition for modifier group DNA |
NL2017294B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Natural cryptic exon removal by pairs of antisense oligonucleotides. |
NL2017295B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Antisense oligomeric compound for Pompe disease |
WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
TWI788312B (en) | 2016-11-23 | 2023-01-01 | 美商阿尼拉製藥公司 | SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
AU2017376950B2 (en) | 2016-12-16 | 2024-02-22 | Alnylam Pharmaceuticals, Inc. | Methods for treating or preventing TTR-associated diseases using transthyretin (TTR) iRNA compositions |
SG11201905508VA (en) | 2017-01-23 | 2019-08-27 | Regeneron Pharma | Hsd17b13 variants and uses thereof |
WO2018183969A1 (en) | 2017-03-30 | 2018-10-04 | California Institute Of Technology | Barcoded rapid assay platform for efficient analysis of candidate molecules and methods of making and using the platform |
TWI801377B (en) | 2017-04-18 | 2023-05-11 | 美商阿尼拉製藥公司 | Methods for the treatment of subjects having a hepatitis b virus (hbv) infection |
AU2018300069A1 (en) | 2017-07-11 | 2020-02-27 | Synthorx, Inc. | Incorporation of unnatural nucleotides and methods thereof |
KR20200028997A (en) | 2017-07-13 | 2020-03-17 | 노오쓰웨스턴 유니버시티 | General and direct method of preparing oligonucleotide-functionalized metal-organic framework nanoparticles |
JP7277432B2 (en) | 2017-07-13 | 2023-05-19 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | Lactate dehydrogenase A (LDHA) iRNA compositions and methods of use thereof |
US20200181220A1 (en) | 2017-08-03 | 2020-06-11 | Synthorx, Inc. | Cytokine conjugates for the treatment of proliferative and infectious diseases |
KR20200089656A (en) | 2017-09-19 | 2020-07-27 | 알닐람 파마슈티칼스 인코포레이티드 | Compositions and methods for treating transthyretin (TTR) mediated amyloidosis |
AU2018360697A1 (en) | 2017-11-01 | 2020-05-14 | Alnylam Pharmaceuticals, Inc. | Complement component C3 iRNA compositions and methods of use thereof |
US20200385719A1 (en) | 2017-11-16 | 2020-12-10 | Alnylam Pharmaceuticals, Inc. | Kisspeptin 1 (kiss1) irna compositions and methods of use thereof |
EP3714054A1 (en) | 2017-11-20 | 2020-09-30 | Alnylam Pharmaceuticals, Inc. | Serum amyloid p component (apcs) irna compositions and methods of use thereof |
BR112020012088A2 (en) | 2017-12-18 | 2020-11-17 | Alnylam Pharmaceuticals, Inc. | compositions of the high mobility group box-1 (hmgb1) and methods of using them |
WO2019147743A1 (en) | 2018-01-26 | 2019-08-01 | Massachusetts Institute Of Technology | Structure-guided chemical modification of guide rna and its applications |
CA3091857A1 (en) | 2018-02-26 | 2019-08-29 | Synthorx, Inc. | Il-15 conjugates and uses thereof |
AU2019247490A1 (en) | 2018-04-06 | 2020-10-22 | Children's Medical Center Corporation | Compositions and methods for somatic cell reprogramming and modulating imprinting |
AU2019266207A1 (en) | 2018-05-07 | 2020-12-17 | Alnylam Pharmaceuticals, Inc. | Extrahepatic delivery |
TW202016304A (en) | 2018-05-14 | 2020-05-01 | 美商阿尼拉製藥公司 | Angiotensinogen (agt) irna compositions and methods of use thereof |
EA202190528A1 (en) | 2018-08-13 | 2021-04-23 | Элнилэм Фармасьютикалз, Инк. | COMPOSITIONS OF HEPATITIS B VIRUS (HBV) dsRNA AGENTS AND METHODS OF THEIR APPLICATION |
US20210348162A1 (en) | 2018-08-16 | 2021-11-11 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
US20220056220A1 (en) | 2018-09-14 | 2022-02-24 | Northwestern University | Programming protein polymerization with dna |
WO2020060986A1 (en) | 2018-09-18 | 2020-03-26 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (khk) irna compositions and methods of use thereof |
EP3856907A1 (en) | 2018-09-28 | 2021-08-04 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases |
US10913951B2 (en) | 2018-10-31 | 2021-02-09 | University of Pittsburgh—of the Commonwealth System of Higher Education | Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure |
WO2020118259A1 (en) | 2018-12-06 | 2020-06-11 | Northwestern University | Protein crystal engineering through dna hybridization interactions |
CN113631709A (en) | 2018-12-20 | 2021-11-09 | 普拉克西斯精密药物股份有限公司 | Compositions and methods for treating KCNT 1-related disorders |
HRP20231338T1 (en) | 2018-12-20 | 2024-02-16 | Vir Biotechnology, Inc. | Combination hbv therapy |
MX2021008628A (en) | 2019-01-16 | 2021-11-17 | Genzyme Corp | Serpinc1 irna compositions and methods of use thereof. |
MX2021009259A (en) | 2019-02-06 | 2021-08-24 | Synthorx Inc | Il-2 conjugates and methods of use thereof. |
US20220339256A1 (en) | 2019-05-13 | 2022-10-27 | Vir Biotechnology, Inc. | Compositions and methods for treating hepatitis b virus (hbv) infection |
US20220211743A1 (en) | 2019-05-17 | 2022-07-07 | Alnylam Pharmaceuticals, Inc. | Oral delivery of oligonucleotides |
JP2022538784A (en) | 2019-06-14 | 2022-09-06 | ザ スクリプス リサーチ インスティテュート | Reagents and methods for replication, transcription and translation in semi-synthetic organisms |
WO2021022109A1 (en) | 2019-08-01 | 2021-02-04 | Alnylam Pharmaceuticals, Inc. | SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
WO2021022108A2 (en) | 2019-08-01 | 2021-02-04 | Alnylam Pharmaceuticals, Inc. | CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
EP4013870A1 (en) | 2019-08-13 | 2022-06-22 | Alnylam Pharmaceuticals, Inc. | Small ribosomal protein subunit 25 (rps25) irna agent compositions and methods of use thereof |
WO2021030706A1 (en) | 2019-08-15 | 2021-02-18 | Synthorx, Inc. | Immuno oncology combination therapies with il-2 conjugates |
CA3148135A1 (en) | 2019-08-23 | 2021-03-04 | Carolina E. CAFFARO | Il-15 conjugates and uses thereof |
MX2022002689A (en) | 2019-09-03 | 2022-04-07 | Alnylam Pharmaceuticals Inc | Compositions and methods for inhibiting expression of the lect2 gene. |
KR20220061158A (en) | 2019-09-10 | 2022-05-12 | 신톡스, 인크. | IL-2 conjugates and methods of use for treating autoimmune diseases |
EP4038189A1 (en) | 2019-10-04 | 2022-08-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing ugt1a1 gene expression |
EP4045652A1 (en) | 2019-10-18 | 2022-08-24 | Alnylam Pharmaceuticals, Inc. | Solute carrier family member irna compositions and methods of use thereof |
EP4048793A1 (en) | 2019-10-22 | 2022-08-31 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
US20230040920A1 (en) | 2019-11-01 | 2023-02-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing dnajb1-prkaca fusion gene expression |
AR120341A1 (en) | 2019-11-01 | 2022-02-09 | Alnylam Pharmaceuticals Inc | COMPOSITIONS OF RNAi AGENTS AGAINST HUNTINGTINE (HTT) AND THEIR METHODS OF USE |
MX2022005251A (en) | 2019-11-04 | 2022-06-08 | Synthorx Inc | Interleukin 10 conjugates and uses thereof. |
EP4055165A1 (en) | 2019-11-06 | 2022-09-14 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases |
JP2023500681A (en) | 2019-11-06 | 2023-01-10 | アルニラム ファーマスーティカルズ インコーポレイテッド | extrahepatic delivery |
EP4061945A1 (en) | 2019-11-22 | 2022-09-28 | Alnylam Pharmaceuticals, Inc. | Ataxin3 (atxn3) rnai agent compositions and methods of use thereof |
EP4073251A1 (en) | 2019-12-13 | 2022-10-19 | Alnylam Pharmaceuticals, Inc. | Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof |
WO2021126734A1 (en) | 2019-12-16 | 2021-06-24 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
US20230057461A1 (en) | 2020-01-27 | 2023-02-23 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Rab13 and net1 antisense oligonucleotides to treat metastatic cancer |
WO2021154941A1 (en) | 2020-01-31 | 2021-08-05 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als) |
CA3170377A1 (en) | 2020-02-10 | 2021-08-19 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing vegf-a expression |
CN115397989A (en) | 2020-02-18 | 2022-11-25 | 阿尔尼拉姆医药品有限公司 | Apolipoprotein C3 (APOC 3) iRNA compositions and methods of use thereof |
EP4114947A1 (en) | 2020-03-05 | 2023-01-11 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases |
WO2021178736A1 (en) | 2020-03-06 | 2021-09-10 | Alnylam Pharmaceuticals, Inc. | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
WO2021188611A1 (en) | 2020-03-18 | 2021-09-23 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant |
CN116209759A (en) | 2020-03-26 | 2023-06-02 | 阿尔尼拉姆医药品有限公司 | Coronavirus iRNA compositions and methods of use thereof |
WO2021202443A2 (en) | 2020-03-30 | 2021-10-07 | Alnylam Pharmaceucticals, Inc. | Compositions and methods for silencing dnajc15 gene expression |
BR112022020145A2 (en) | 2020-04-06 | 2023-01-03 | Alnylam Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR SILENCING THE MYOC EXPRESSION |
EP4133077A1 (en) | 2020-04-07 | 2023-02-15 | Alnylam Pharmaceuticals, Inc. | Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof |
WO2021207189A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing scn9a expression |
WO2021206917A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
KR20230018377A (en) | 2020-04-27 | 2023-02-07 | 알닐람 파마슈티칼스 인코포레이티드 | Apolipoprotein E (APOE) IRNA preparation composition and method of use thereof |
KR20230017789A (en) | 2020-04-30 | 2023-02-06 | 알닐람 파마슈티칼스 인코포레이티드 | Complement Factor B (CFB) iRNA Compositions and Methods of Use Thereof |
WO2021231673A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2) |
EP4150089A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1) |
EP4150078A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl) |
WO2021231679A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2) |
CA3162416C (en) | 2020-05-15 | 2023-07-04 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1) |
EP4150077A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1) |
EP4150090A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of otoferlin (otof) |
EP4150076A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2) |
EP4153746A1 (en) | 2020-05-21 | 2023-03-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting marc1 gene expression |
AR122534A1 (en) | 2020-06-03 | 2022-09-21 | Triplet Therapeutics Inc | METHODS FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY |
EP4161552A1 (en) | 2020-06-05 | 2023-04-12 | The Broad Institute, Inc. | Compositions and methods for treating neoplasia |
EP4162050A1 (en) | 2020-06-09 | 2023-04-12 | Alnylam Pharmaceuticals, Inc. | Rnai compositions and methods of use thereof for delivery by inhalation |
CN116209760A (en) | 2020-06-18 | 2023-06-02 | 阿尔尼拉姆医药品有限公司 | Xanthine Dehydrogenase (XDH) iRNA compositions and methods of use thereof |
BR112022026316A2 (en) | 2020-06-24 | 2023-03-07 | Vir Biotechnology Inc | ENGINEERED HEPATITIS B VIRUS NEUTRALIZING ANTIBODIES AND THEIR USES |
TW202216203A (en) | 2020-06-25 | 2022-05-01 | 美商欣爍克斯公司 | Immuno oncology combination therapy with il-2 conjugates and anti-egfr antibodies |
US20230257745A1 (en) | 2020-07-10 | 2023-08-17 | Alnylam Pharmaceuticals, Inc. | Circular siRNAs |
EP4217489A1 (en) | 2020-09-24 | 2023-08-02 | Alnylam Pharmaceuticals, Inc. | Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof |
TW202229552A (en) | 2020-10-05 | 2022-08-01 | 美商艾拉倫製藥股份有限公司 | G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof |
MX2023004032A (en) | 2020-10-09 | 2023-04-27 | Synthorx Inc | Immuno oncology therapies with il-2 conjugates. |
MX2023004029A (en) | 2020-10-09 | 2023-04-27 | Synthorx Inc | Immuno oncology combination therapy with il-2 conjugates and pembrolizumab. |
EP4232581A1 (en) | 2020-10-21 | 2023-08-30 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating primary hyperoxaluria |
EP4232582A1 (en) | 2020-10-23 | 2023-08-30 | Alnylam Pharmaceuticals, Inc. | Mucin 5b (muc5b) irna compositions and methods of use thereof |
JP2023549500A (en) | 2020-11-13 | 2023-11-27 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | Coagulation factor V (F5) iRNA composition and method of use thereof |
TW202237150A (en) | 2020-12-01 | 2022-10-01 | 美商艾拉倫製藥股份有限公司 | Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
EP4259795A1 (en) | 2020-12-08 | 2023-10-18 | Alnylam Pharmaceuticals, Inc. | Coagulation factor x (f10) irna compositions and methods of use thereof |
CA3206285A1 (en) | 2020-12-23 | 2022-06-30 | Flagship Pioneering, Inc. | Compositions of modified trems and uses thereof |
WO2022147214A2 (en) | 2020-12-31 | 2022-07-07 | Alnylam Pharmaceuticals, Inc. | Cyclic-disulfide modified phosphate based oligonucleotide prodrugs |
EP4271695A2 (en) | 2020-12-31 | 2023-11-08 | Alnylam Pharmaceuticals, Inc. | 2'-modified nucleoside based oligonucleotide prodrugs |
WO2022150260A1 (en) | 2021-01-05 | 2022-07-14 | Alnylam Pharmaceuticals, Inc. | COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
WO2022174000A2 (en) | 2021-02-12 | 2022-08-18 | Alnylam Pharmaceuticals, Inc. | Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases |
TW202245843A (en) | 2021-02-12 | 2022-12-01 | 美商欣爍克斯公司 | Skin cancer combination therapy with il-2 conjugates and cemiplimab |
EP4291243A1 (en) | 2021-02-12 | 2023-12-20 | Synthorx, Inc. | Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof |
JP2024509783A (en) | 2021-02-25 | 2024-03-05 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | Prion protein (PRNP) IRNA compositions and methods of use thereof |
WO2022182574A1 (en) | 2021-02-26 | 2022-09-01 | Alnylam Pharmaceuticals, Inc. | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
WO2022187435A1 (en) | 2021-03-04 | 2022-09-09 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
WO2022192519A1 (en) | 2021-03-12 | 2022-09-15 | Alnylam Pharmaceuticals, Inc. | Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof |
EP4304640A1 (en) | 2021-03-12 | 2024-01-17 | Northwestern University | Antiviral vaccines using spherical nucleic acids |
CA3214499A1 (en) | 2021-03-29 | 2022-10-06 | Alnylam Pharmaceuticals, Inc. | Huntingtin (htt) irna agent compositions and methods of use thereof |
KR20240009393A (en) | 2021-03-31 | 2024-01-22 | 엔트라다 테라퓨틱스, 인크. | Cyclic cell penetrating peptide |
WO2022212153A1 (en) | 2021-04-01 | 2022-10-06 | Alnylam Pharmaceuticals, Inc. | Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof |
EP4330392A1 (en) | 2021-04-26 | 2024-03-06 | Alnylam Pharmaceuticals, Inc. | Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof |
WO2022232343A1 (en) | 2021-04-29 | 2022-11-03 | Alnylam Pharmaceuticals, Inc. | Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof |
WO2022235537A1 (en) | 2021-05-03 | 2022-11-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating transthyretin (ttr) mediated amyloidosis |
AU2022271873A1 (en) | 2021-05-10 | 2024-01-04 | Entrada Therapeutics, Inc. | Compositions and methods for intracellular therapeutics |
WO2022240760A2 (en) | 2021-05-10 | 2022-11-17 | Entrada Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR MODULATING mRNA SPLICING |
WO2022240721A1 (en) | 2021-05-10 | 2022-11-17 | Entrada Therapeutics, Inc. | Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity |
EP4341401A1 (en) | 2021-05-18 | 2024-03-27 | Alnylam Pharmaceuticals, Inc. | Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof |
WO2022246023A1 (en) | 2021-05-20 | 2022-11-24 | Korro Bio, Inc. | Methods and compositions for adar-mediated editing |
WO2022256283A2 (en) | 2021-06-01 | 2022-12-08 | Korro Bio, Inc. | Methods for restoring protein function using adar |
WO2022256395A1 (en) | 2021-06-02 | 2022-12-08 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
TW202313679A (en) | 2021-06-03 | 2023-04-01 | 美商欣爍克斯公司 | Head and neck cancer combination therapy comprising an il-2 conjugate and a pd-1 antagonist |
BR112023025224A2 (en) | 2021-06-04 | 2024-02-27 | Alnylam Pharmaceuticals Inc | HUMAN CHROMOSOME 9 (C9ORF72) OPEN READING BOARD 72 IRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
WO2022260939A2 (en) | 2021-06-08 | 2022-12-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders |
IL309001A (en) | 2021-06-23 | 2024-02-01 | Entrada Therapeutics Inc | Antisense compounds and methods for targeting cug repeats |
US20230194709A9 (en) | 2021-06-29 | 2023-06-22 | Seagate Technology Llc | Range information detection using coherent pulse sets with selected waveform characteristics |
WO2023278410A1 (en) | 2021-06-29 | 2023-01-05 | Korro Bio, Inc. | Methods and compositions for adar-mediated editing |
WO2023283403A2 (en) | 2021-07-09 | 2023-01-12 | Alnylam Pharmaceuticals, Inc. | Bis-rnai compounds for cns delivery |
WO2023003805A1 (en) | 2021-07-19 | 2023-01-26 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder |
KR20240036041A (en) | 2021-07-21 | 2024-03-19 | 알닐람 파마슈티칼스 인코포레이티드 | Metabolic Disorder-Associated Target Gene iRNA Composition and Methods of Using Same |
IL309905A (en) | 2021-07-23 | 2024-03-01 | Alnylam Pharmaceuticals Inc | Beta-catenin (ctnnb1) irna compositions and methods of use thereof |
WO2023009687A1 (en) | 2021-07-29 | 2023-02-02 | Alnylam Pharmaceuticals, Inc. | 3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof |
CN117795074A (en) | 2021-08-03 | 2024-03-29 | 阿尔尼拉姆医药品有限公司 | Transthyretin (TTR) iRNA compositions and methods of use thereof |
TW202337474A (en) | 2021-08-04 | 2023-10-01 | 美商艾拉倫製藥股份有限公司 | Irna compositions and methods for silencing angiotensinogen (agt) |
AR126771A1 (en) | 2021-08-13 | 2023-11-15 | Alnylam Pharmaceuticals Inc | RNAi COMPOSITIONS AGAINST FACTOR XII (F12) AND THEIR METHODS OF USE |
CA3229661A1 (en) | 2021-09-01 | 2023-03-09 | Xiang Li | Compounds and methods for skipping exon 44 in duchenne muscular dystrophy |
WO2023044370A2 (en) | 2021-09-17 | 2023-03-23 | Alnylam Pharmaceuticals, Inc. | Irna compositions and methods for silencing complement component 3 (c3) |
WO2023044094A1 (en) | 2021-09-20 | 2023-03-23 | Alnylam Pharmaceuticals, Inc. | Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof |
WO2023064530A1 (en) | 2021-10-15 | 2023-04-20 | Alnylam Pharmaceuticals, Inc. | Extra-hepatic delivery irna compositions and methods of use thereof |
WO2023069603A1 (en) | 2021-10-22 | 2023-04-27 | Korro Bio, Inc. | Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing |
WO2023076451A1 (en) | 2021-10-29 | 2023-05-04 | Alnylam Pharmaceuticals, Inc. | Complement factor b (cfb) irna compositions and methods of use thereof |
TW202334418A (en) | 2021-10-29 | 2023-09-01 | 美商艾拉倫製藥股份有限公司 | Huntingtin (htt) irna agent compositions and methods of use thereof |
WO2023092060A1 (en) | 2021-11-18 | 2023-05-25 | Cornell University | Microrna-dependent mrna switches for tissue-specific mrna-based therapies |
WO2023122573A1 (en) | 2021-12-20 | 2023-06-29 | Synthorx, Inc. | Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab |
WO2023122750A1 (en) | 2021-12-23 | 2023-06-29 | Synthorx, Inc. | Cancer combination therapy with il-2 conjugates and cetuximab |
WO2023141314A2 (en) | 2022-01-24 | 2023-07-27 | Alnylam Pharmaceuticals, Inc. | Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof |
WO2023220744A2 (en) | 2022-05-13 | 2023-11-16 | Alnylam Pharmaceuticals, Inc. | Single-stranded loop oligonucleotides |
WO2024006999A2 (en) | 2022-06-30 | 2024-01-04 | Alnylam Pharmaceuticals, Inc. | Cyclic-disulfide modified phosphate based oligonucleotide prodrugs |
WO2024039776A2 (en) | 2022-08-18 | 2024-02-22 | Alnylam Pharmaceuticals, Inc. | Universal non-targeting sirna compositions and methods of use thereof |
WO2024059165A1 (en) | 2022-09-15 | 2024-03-21 | Alnylam Pharmaceuticals, Inc. | 17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof |
WO2024073732A1 (en) | 2022-09-30 | 2024-04-04 | Alnylam Pharmaceuticals, Inc. | Modified double-stranded rna agents |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1978953A (en) * | 1928-10-17 | 1934-10-30 | Du Pont | Method of preparing an alkali metal perborate |
DE548432C (en) * | 1928-10-17 | 1932-04-12 | Degussa | Production of a perborate |
US3327684A (en) * | 1963-03-11 | 1967-06-27 | Fairchild Camera Instr Co | Masking apparatus for spray coating |
FR2226460B1 (en) * | 1973-04-20 | 1976-12-17 | Interox | |
JPS5315717B2 (en) * | 1973-12-20 | 1978-05-26 | ||
DE2652776A1 (en) * | 1975-05-13 | 1978-05-24 | Interox Chemicals Ltd | Stabilised sodium percarbonate mfr. - by precipitating in presence of silicate, then increasing the silicate content of the mother liquor |
LU72575A1 (en) * | 1975-05-23 | 1977-02-10 | ||
DE2810379C3 (en) * | 1978-03-10 | 1980-12-11 | Degussa Ag, 6000 Frankfurt | Process for the production of stabilized sodium percarbonate |
DE2651442C3 (en) * | 1976-11-11 | 1979-11-15 | Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt | Sodium Percarbonate Particles |
US4156039A (en) * | 1976-11-11 | 1979-05-22 | Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler | Sodium percarbonate particles (A) |
DE2712139C3 (en) * | 1977-03-19 | 1982-05-19 | Degussa Ag, 6000 Frankfurt | Sodium percarbonate layer particles |
LU76548A1 (en) * | 1977-01-10 | 1978-09-18 | ||
DE2800760C2 (en) * | 1978-01-09 | 1983-01-27 | Degussa Ag, 6000 Frankfurt | Process for the production of sodium percarbonate from a soda solution or suspension |
GB1575792A (en) * | 1978-01-10 | 1980-10-01 | Interox | Peroxygen compounds |
DE3321082C2 (en) * | 1982-06-10 | 1996-08-22 | Kao Corp | Bleach Cleaner |
GB2123044B (en) * | 1982-06-10 | 1986-02-05 | Kao Corp | Bleaching detergent composition |
EP0117578A3 (en) * | 1983-02-23 | 1985-01-30 | Shionogi & Co., Ltd. | Azole-substituted alcohol derivatives |
US4952232A (en) * | 1987-04-29 | 1990-08-28 | E. I. Du Pont De Nemours And Company | Antifungal carbinols |
DE3784787T2 (en) * | 1986-06-23 | 1994-01-20 | Du Pont Merck Pharma | Fungicidal carbinols. |
DE3720277A1 (en) * | 1987-06-19 | 1988-12-29 | Degussa | METHOD FOR REDUCING THE TENSION TO BAKING UP PARTICULATE ACTIVE OXYGEN COMPOUNDS |
DE3813874A1 (en) * | 1987-07-10 | 1989-01-19 | Bayer Ag | HYDROXYALKYL-AZOLYL DERIVATIVES |
DE3921481A1 (en) * | 1989-06-30 | 1991-01-03 | Bayer Ag | HYDROXYETHYL-CYCLOPROPYL-AZOLYL DERIVATIVES |
WO1991012000A1 (en) * | 1990-02-13 | 1991-08-22 | E.I. Du Pont De Nemours And Company | ANILINE DERIVATIVES OF α-STYRYL CARBINOLS AS ANTIFUNGAL AGENTS |
JP2636496B2 (en) * | 1990-11-21 | 1997-07-30 | 花王 株式会社 | Stable sodium percarbonate particles and method for producing the same |
-
1993
- 1993-04-10 DE DE4311944A patent/DE4311944A1/en not_active Withdrawn
-
1994
- 1994-02-28 AT AT94909085T patent/ATE156096T1/en active
- 1994-02-28 ES ES94909085T patent/ES2106515T3/en not_active Expired - Lifetime
- 1994-02-28 PL PL94311035A patent/PL173925B1/en unknown
- 1994-02-28 CN CN94191734A patent/CN1120832A/en active Pending
- 1994-02-28 AU AU62078/94A patent/AU6207894A/en not_active Abandoned
- 1994-02-28 KR KR1019950704418A patent/KR100308473B1/en not_active IP Right Cessation
- 1994-02-28 CZ CZ952498A patent/CZ249895A3/en unknown
- 1994-02-28 JP JP52265894A patent/JP3599737B2/en not_active Expired - Fee Related
- 1994-02-28 US US08/525,782 patent/US5658873A/en not_active Expired - Lifetime
- 1994-02-28 EP EP94909085A patent/EP0693039B1/en not_active Expired - Lifetime
- 1994-02-28 CA CA002159991A patent/CA2159991A1/en not_active Abandoned
- 1994-02-28 DE DE59403562T patent/DE59403562D1/en not_active Expired - Lifetime
- 1994-02-28 TW TW083101684A patent/TW265320B/zh active
- 1994-02-28 WO PCT/EP1994/000576 patent/WO1994024044A1/en not_active Application Discontinuation
- 1994-04-04 TR TR00294/94A patent/TR27402A/en unknown
- 1994-04-07 SI SI9400166A patent/SI9400166A/en unknown
-
1995
- 1995-10-09 FI FI954808A patent/FI954808A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
TR27402A (en) | 1995-02-28 |
FI954808A (en) | 1995-10-09 |
EP0693039B1 (en) | 1997-07-30 |
ATE156096T1 (en) | 1997-08-15 |
CZ249895A3 (en) | 1996-04-17 |
TW265320B (en) | 1995-12-11 |
WO1994024044A1 (en) | 1994-10-27 |
PL173925B1 (en) | 1998-05-29 |
US5658873A (en) | 1997-08-19 |
KR960701801A (en) | 1996-03-28 |
CN1120832A (en) | 1996-04-17 |
JPH08508707A (en) | 1996-09-17 |
DE4311944A1 (en) | 1994-10-13 |
PL311035A1 (en) | 1996-01-22 |
FI954808A0 (en) | 1995-10-09 |
ES2106515T3 (en) | 1997-11-01 |
EP0693039A1 (en) | 1996-01-24 |
KR100308473B1 (en) | 2002-07-02 |
JP3599737B2 (en) | 2004-12-08 |
AU6207894A (en) | 1994-11-08 |
DE59403562D1 (en) | 1997-09-04 |
SI9400166A (en) | 1994-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5658873A (en) | Coated sodium percarbonate particles, a process for their production and detergent, cleaning and bleaching compositions containing them | |
US3951838A (en) | Silica sol stabilizers for improving the stability of sodium percarbonate in solid bleaches and detergents | |
KR100309586B1 (en) | Coated sodium percarbonate particles, preparation method thereof and detergents, detergents and bleaches comprising the same | |
US6113805A (en) | Coated sodium percarbonate particles, process for the production thereof and use thereof | |
US6521583B1 (en) | Coated sodium percarbonate particles, process for their preparation, their use in detergent compositions and detergent compositions containing them | |
EP1807344B1 (en) | Sodium percarbonate particles having a shell layer comprising thiosulfate | |
KR101434347B1 (en) | Coated sodium percarbonate particles | |
US5902682A (en) | Coated sodium percarbonate particles, a process for their preparation and their use | |
EP0737165B1 (en) | Process for stabilising particulate alkali metal percarbonate | |
KR101434343B1 (en) | Coated sodium percarbonate particle | |
US5556834A (en) | Percarbonate particles stabilized by coating with an aqueous solution containing a silicate and a boric acid | |
CA2180288A1 (en) | Coated alkali metal peroxo salts and process for producing the same | |
US6054066A (en) | Process for preparing a sodium percarbonate product | |
US7371717B2 (en) | Process for preparing coated alkali metal percarbonate, coated alkali metal percarbonate obtainable by this process, its use in detergent compositions, and detergent compositions containing it | |
US5670470A (en) | Percarbonate stabilised by coating with an aqueous solution of phosphate and boron compounds | |
US5744055A (en) | Stable monopersulfate triple salt and its method of preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |